

Johan Neyts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2410605/publications.pdf>

Version: 2024-02-01

693
papers

34,480
citations

4136

87
h-index

9854

141
g-index

844
all docs

844
docs citations

844
times ranked

34599
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2794-2808.	2.9	52
2	Cytidine nucleoside analog is an effective antiviral drug against <i>Trichomonas</i> virus. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 191-198.	1.5	6
3	Synthesis, X-ray crystallographic analysis, DFT studies and biological evaluation of triazolopyrimidines and 2-anilino pyrimidines. <i>Journal of Molecular Structure</i> , 2022, 1252, 132092.	1.8	2
4	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. <i>Science</i> , 2022, 375, 449-454.	6.0	108
5	Advances and gaps in SARS-CoV-2 infection models. <i>PLoS Pathogens</i> , 2022, 18, e1010161.	2.1	61
6	Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings. <i>Biomedicines</i> , 2022, 10, 268.	1.4	2
7	Synthesis and antiviral activities of quinazolinamine-coumarin conjugates toward chikungunya and hepatitis C viruses. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114164.	2.6	11
8	The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters. <i>Antiviral Research</i> , 2022, 198, 105253.	1.9	104
9	Restriction of Viral Replication, Rather than T Cell Immunopathology, Drives Lethality in Murine Norovirus CR6-Infected STAT1-Deficient Mice. <i>Journal of Virology</i> , 2022, 96, jvi0206521.	1.5	1
10	Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. <i>Antiviral Research</i> , 2022, 198, 105252.	1.9	302
11	Synthesis, Structure-Activity Relationships, and Antiviral Profiling of 1-Heteroaryl-2-Alkoxyphenyl Analogs as Inhibitors of SARS-CoV-2 Replication. <i>Molecules</i> , 2022, 27, 1052.	1.7	4
12	Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. <i>Journal of the American Chemical Society</i> , 2022, 144, 2905-2920.	6.6	118
13	Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures. <i>Journal of Medical Virology</i> , 2022, 94, 3101-3111.	2.5	13
14	The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model. <i>Communications Biology</i> , 2022, 5, 225.	2.0	10
15	MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters. <i>Frontiers in Immunology</i> , 2022, 13, 845969.	2.2	16
16	Ivermectin Does Not Protect against SARS-CoV-2 Infection in the Syrian Hamster Model. <i>Microorganisms</i> , 2022, 10, 633.	1.6	3
17	Biodistribution and environmental safety of a live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 215-224.	1.8	5
18	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. <i>Antiviral Research</i> , 2022, 202, 105311.	1.9	8

#	ARTICLE	IF	CITATIONS
19	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 719.	5.8	86
20	A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. <i>Molecular Therapy</i> , 2022, 30, 2968-2983.	3.7	20
21	Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 855-864.	1.3	10
22	SARS-CoV-2 Virion Infectivity and Cytokine Production in Primary Human Airway Epithelial Cells. <i>Viruses</i> , 2022, 14, 951.	1.5	6
23	Organotropic dendrons with high potency as HIV-1, HIV-2 and EV-A71 cell entry inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114414.	2.6	1
24	A High-Throughput Yellow Fever Neutralization Assay. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	8
25	Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort. <i>Scientific Data</i> , 2022, 9, .	2.4	17
26	Computer-Aided Design and Synthesis of (Functionalized quinazoline)â€“(Î±-substituted) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (Sciences, 2022, 23, 7646.	1.8	0
27	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. <i>Science</i> , 2022, 377, 735-742.	6.0	85
28	Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model. <i>iScience</i> , 2022, 25, 104705.	1.9	8
29	SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging. <i>Nature Chemical Biology</i> , 2021, 17, 222-228.	3.9	215
30	Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Identification of active compounds. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110268.	0.3	3
31	Screening and in vitro antiviral assessment of small molecules against fluorescent protein-expressing Bunyamwera virus in a cell-based assay using high-content imaging. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110334.	0.3	3
32	Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies. <i>Antiviral Chemistry and Chemotherapy</i> , 2021, 29, 204020662110251.	0.3	1
33	Identification of host factors binding to dengue and Zika virus subgenomic RNA by efficient yeast three-hybrid screens of the human ORFeome. <i>RNA Biology</i> , 2021, 18, 732-744.	1.5	7
34	Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 1793-1802.	2.1	77
35	Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains. <i>Nature Communications</i> , 2021, 12, 916.	5.8	80
36	Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. <i>Microorganisms</i> , 2021, 9, 734.	1.6	13

#	ARTICLE	IF	CITATIONS
37	Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2. <i>Nature Genetics</i> , 2021, 53, 435-444.	9.4	162
38	Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1096-1110.	2.5	101
39	Infection of zebrafish larvae with human norovirus and evaluation of the in vivo efficacy of small-molecule inhibitors. <i>Nature Protocols</i> , 2021, 16, 1830-1849.	5.5	20
40	Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. <i>EBioMedicine</i> , 2021, 66, 103288.	2.7	21
41	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
42	ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model. <i>Biochemical and Biophysical Research Communications</i> , 2021, 555, 134-139.	1.0	30
43	In vitro activity of itraconazole against SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 4454-4460.	2.5	30
44	Chemische Evolution antiviraler Wirkstoffe gegen Enterovirus D68 durch Proteintemplat-gesteuerte Knoevenagelreaktionen. <i>Angewandte Chemie</i> , 2021, 133, 13405-13413.	1.6	1
45	COVID-19 and the intensive care unit: vaccines to the rescue. <i>Intensive Care Medicine</i> , 2021, 47, 786-789.	3.9	8
46	Chemical Evolution of Antivirals Against Enterovirus D68 through Protein-Templated Knoevenagel Reactions. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 13294-13301.	7.2	9
47	Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters. <i>EBioMedicine</i> , 2021, 68, 103403.	2.7	102
48	Structural Insights into the Mechanisms of Action of Functionally Distinct Classes of Chikungunya Virus Nonstructural Protein 1 Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0256620.	1.4	9
49	Multivalent Tryptophan- and Tyrosine-Containing [60]Fullerene Hexa-Adducts as Dual HIV and Enterovirus A71 Entry Inhibitors. <i>Chemistry - A European Journal</i> , 2021, 27, 10700-10710.	1.7	9
50	Discovery of novel furo[2,3- <i>b</i>]pyrimidin-2-one-1,3,4-oxadiazole hybrid derivatives as dual antiviral and anticancer agents that induce apoptosis. <i>Archiv Der Pharmazie</i> , 2021, 354, e2100146.	2.1	19
51	Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections. <i>Microorganisms</i> , 2021, 9, 1599.	1.6	12
52	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. <i>Nature Communications</i> , 2021, 12, 4117.	5.8	170
53	Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. <i>Journal of Infectious Diseases</i> , 2021, 224, 749-753.	1.9	95
54	Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 10027-10046.	2.9	7

#	ARTICLE	IF	CITATIONS
55	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
56	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021, 597, 97-102.	13.7	385
57	A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice. <i>JHEP Reports</i> , 2021, 3, 100295.	2.6	7
58	Structure-Activity Relationship Studies on Novel Antiviral Agents for Norovirus Infections. <i>Microorganisms</i> , 2021, 9, 1795.	1.6	1
59	A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents. <i>Antiviral Research</i> , 2021, 192, 105122.	1.9	47
60	A highly potent antibody effective against SARS-CoV-2 variants of concern. <i>Cell Reports</i> , 2021, 37, 109814.	2.9	39
61	Animal experiments show impact of vaccination on reduction of SARS-CoV-2 virus circulation: A model for vaccine development?. <i>Biologicals</i> , 2021, 73, 1-7.	0.5	4
62	Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. <i>Antiviral Research</i> , 2021, 193, 105142.	1.9	19
63	Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. <i>Antiviral Research</i> , 2021, 193, 105127.	1.9	27
64	A Novel Class of Norovirus Inhibitors Targeting the Viral Protease with Potent Antiviral Activity In Vitro and In Vivo. <i>Viruses</i> , 2021, 13, 1852.	1.5	7
65	Assessing <i>In Vitro</i> Resistance Development in Enterovirus A71 in the Context of Combination Antiviral Treatment. <i>ACS Infectious Diseases</i> , 2021, 7, 2801-2806.	1.8	6
66	Broad betacoronavirus neutralization by a stem helix-specific human antibody. <i>Science</i> , 2021, 373, 1109-1116.	6.0	262
67	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors. <i>European Journal of Medicinal Chemistry</i> , 2021, 221, 113494.	2.6	15
68	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. <i>EBioMedicine</i> , 2021, 72, 103595.	2.7	91
69	Comparative analysis of the molecular mechanism of resistance to vapendavir across a panel of picornavirus species. <i>Antiviral Research</i> , 2021, 195, 105177.	1.9	10
70	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. <i>Cell Research</i> , 2021, 31, 272-290.	5.7	229
71	A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. <i>Nature</i> , 2021, 590, 320-325.	13.7	148
72	Discovery of a Novel Class of Norovirus Inhibitors with High Barrier of Resistance. <i>Pharmaceuticals</i> , 2021, 14, 1006.	1.7	0

#	ARTICLE	IF	CITATIONS
73	A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. <i>Nature</i> , 2021, 598, 504-509.	13.7	90
74	An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models. <i>Science Translational Medicine</i> , 2021, 13, eabi7826.	5.8	41
75	Clinical practices underlie COVID-19 patient respiratory microbiome composition and its interactions with the host. <i>Nature Communications</i> , 2021, 12, 6243.	5.8	42
76	Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. <i>Emerging Microbes and Infections</i> , 2021, 10, 2279-2290.	3.0	6
77	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. <i>Global Health Action</i> , 2021, 14, 2008139.	0.7	5
78	Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets. <i>Biochemical Pharmacology</i> , 2020, 174, 113777.	2.0	14
79	Design, Synthesis and Discovery of <i>N,N</i> -Carbazoyl-urea Inhibitors of Zika NS5 Methyltransferase and Virus Replication. <i>ChemMedChem</i> , 2020, 15, 385-390.	1.6	16
80	Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 349-368.	2.9	20
81	GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5: Entomological aspects. <i>Antiviral Research</i> , 2020, 174, 104670.	1.9	19
82	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26955-26965.	3.3	240
83	Animal models for COVID-19. <i>Nature</i> , 2020, 586, 509-515.	13.7	705
84	Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. <i>Antiviral Research</i> , 2020, 182, 104924.	1.9	33
85	STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. <i>Nature Communications</i> , 2020, 11, 5838.	5.8	225
86	Increased IL-10-producing regulatory T cells are characteristic of severe cases of COVID-19. <i>Clinical and Translational Immunology</i> , 2020, 9, e1204.	1.7	59
87	Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3189-3193.	1.3	5
88	Establishing a Unified COVID-19 "Immunome": Integrating Coronavirus Pathogenesis and Host Immunopathology. <i>Frontiers in Immunology</i> , 2020, 11, 1642.	2.2	11
89	Diketo acids inhibit the cap-snatching endonuclease of several Bunyavirales. <i>Antiviral Research</i> , 2020, 183, 104947.	1.9	22
90	Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957.	6.0	504

#	ARTICLE	IF	CITATIONS
91	A dengue type 2 reporter virus assay amenable to high-throughput screening. <i>Antiviral Research</i> , 2020, 183, 104929.	1.9	13
92	Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. <i>Nature Communications</i> , 2020, 11, 4253.	5.8	43
93	Enterovirus Inhibition by Hinged Aromatic Compounds with Polynuclei. <i>Molecules</i> , 2020, 25, 3821.	1.7	1
94	Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
95	Medical treatment options for COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 209-214.	0.4	39
96	Antiviral and Cytotoxic Activity of Different Plant Parts of Banana (<i>Musa</i> spp.). <i>Viruses</i> , 2020, 12, 549.	1.5	8
97	Antibacterial, Antifungal, Antiviral, and Anthelmintic Activities of Medicinal Plants of Nepal Selected Based on Ethnobotanical Evidence. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-14.	0.5	44
98	Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2196-2203.	1.4	11
99	Reverse engineering synthetic antiviral amyloids. <i>Nature Communications</i> , 2020, 11, 2832.	5.8	25
100	Quinolinecarboxamides Inhibit the Replication of the Bovine Viral Diarrhea Virus by Targeting a Hot Spot for the Inhibition of Pestivirus Replication in the RNA-Dependent RNA Polymerase. <i>Molecules</i> , 2020, 25, 1283.	1.7	8
101	Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. <i>European Journal of Medicinal Chemistry</i> , 2020, 195, 112198.	2.6	14
102	Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 906-912.	1.3	16
103	The Development of RNA-KISS, a Mammalian Three-Hybrid Method to Detect RNA-Protein Interactions in Living Mammalian Cells. <i>Journal of Proteome Research</i> , 2020, 19, 2529-2538.	1.8	4
104	A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. <i>BMC Medicine</i> , 2020, 18, 191.	2.3	47
105	Rational modifications, synthesis and biological evaluation of new potential antivirals for RSV designed to target the M2-1 protein. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115401.	1.4	4
106	A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. <i>Emerging Microbes and Infections</i> , 2020, 9, 520-533.	3.0	21
107	Î±-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4562-4578.	2.9	437
108	Pan-viral protection against arboviruses by activating skin macrophages at the inoculation site. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	25

#	ARTICLE	IF	CITATIONS
109	Regioselective convergent synthesis of 2-arylidene thiazolo[3,2- <i>c</i>]pyrimidines as potential anti-chikungunya agents. <i>RSC Advances</i> , 2020, 10, 5191-5195.	1.7	5
110	A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. <i>MBio</i> , 2020, 11, .	1.8	30
111	Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C. <i>PLoS Biology</i> , 2020, 18, e3000904.	2.6	17
112	Title is missing!. , 2020, 18, e3000904.		0
113	Title is missing!. , 2020, 18, e3000904.		0
114	Title is missing!. , 2020, 18, e3000904.		0
115	Title is missing!. , 2020, 18, e3000904.		0
116	Title is missing!. , 2020, 18, e3000904.		0
117	Title is missing!. , 2020, 18, e3000904.		0
118	Identification of fukinolic acid from <i>Cimicifuga heracleifolia</i> and its derivatives as novel antiviral compounds against enterovirus A71 infection. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 128-136.	1.1	21
119	New HSV-1 Anti-Viral 1 st -Homocarbocyclic Nucleoside Analogs with an Optically Active Substituted Bicyclo[2.2.1]Heptane Fragment as a Glycoside Moiety. <i>Molecules</i> , 2019, 24, 2446.	1.7	9
120	Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence. <i>Emerging Microbes and Infections</i> , 2019, 8, 1076-1085.	3.0	10
121	Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. <i>Journal of Experimental Medicine</i> , 2019, 216, 2057-2070.	4.2	127
122	ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas. <i>Global Health Action</i> , 2019, 12, 1666566.	0.7	13
123	2019 meeting of the global virus network. <i>Antiviral Research</i> , 2019, 172, 104645.	1.9	5
124	Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 10833-10847.	2.9	9
125	A robust human norovirus replication model in zebrafish larvae. <i>PLoS Pathogens</i> , 2019, 15, e1008009.	2.1	112
126	GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus. <i>Antiviral Research</i> , 2019, 172, 104610.	1.9	18

#	ARTICLE	IF	CITATIONS
127	Isolation of phenanthrenes and identification of phorbol ester derivatives as potential anti-CHIKV agents using FBMN and NAP from <i>Sagotia racemosa</i> . <i>Phytochemistry</i> , 2019, 167, 112101.	1.4	4
128	GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o'nyong-nyong virus. <i>Antiviral Research</i> , 2019, 172, 104611.	1.9	23
129	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 558-563.	1.3	16
130	Antiviral Compounds from <i>Codiaeum peltatum</i> Targeted by a Multi-informative Molecular Networks Approach. <i>Journal of Natural Products</i> , 2019, 82, 330-340.	1.5	28
131	Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum. <i>Antiviral Research</i> , 2019, 168, 210-214.	1.9	9
132	A novel druggable interprotomer pocket in the capsid of rhino- and enteroviruses. <i>PLoS Biology</i> , 2019, 17, e3000281.	2.6	36
133	Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. <i>PLoS Pathogens</i> , 2019, 15, e1007760.	2.1	26
134	A Viral Polymerase Inhibitor Reduces Zika Virus Replication in the Reproductive Organs of Male Mice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2122.	1.8	11
135	GloPID-R report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics. <i>Antiviral Research</i> , 2019, 166, 66-81.	1.9	27
136	Targeting the Viral Polymerase of Diarrhea-Causing Viruses as a Strategy to Develop a Single Broad-Spectrum Antiviral Therapy. <i>Viruses</i> , 2019, 11, 173.	1.5	18
137	Structural and functional similarities in bunyaviruses: Perspectives for pan-bunyavirus antivirals. <i>Reviews in Medical Virology</i> , 2019, 29, e2039.	3.9	21
138	Limited evolution of the yellow fever virus 17d in a mouse infection model. <i>Emerging Microbes and Infections</i> , 2019, 8, 1734-1746.	3.0	18
139	F-102 Antivirals, a lot has been achieved, yet a long way to go. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 43-43.	0.9	0
140	A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase. <i>Scientific Reports</i> , 2019, 9, 18413.	1.6	8
141	Antiviral effects of selected nucleoside analogues against human parechoviruses A1 and A3. <i>Antiviral Research</i> , 2019, 162, 51-53.	1.9	6
142	Progress in human picornavirus research: New findings from the AIROPico consortium. <i>Antiviral Research</i> , 2019, 161, 100-107.	1.9	3
143	Pyrimethamine inhibits rabies virus replication in vitro. <i>Antiviral Research</i> , 2019, 161, 1-9.	1.9	15
144	Mannitol treatment is not effective in therapy of rabies virus infection in mice. <i>Vaccine</i> , 2019, 37, 4710-4714.	1.7	7

#	ARTICLE	IF	CITATIONS
145	The path towards effective antivirals against rabies. <i>Vaccine</i> , 2019, 37, 4660-4662.	1.7	9
146	Chikungunya virus resistant to the antiviral favipiravir is severely attenuated in mosquitoes. <i>Access Microbiology</i> , 2019, 1, .	0.2	0
147	A novel class of small molecule inhibitors targeting the chikungunya virus capping machinery with a high barrier to resistance. <i>Access Microbiology</i> , 2019, 1, .	0.2	0
148	Hepatitis E virus replication and interferon responses in human placental cells. <i>Hepatology Communications</i> , 2018, 2, 173-187.	2.0	40
149	Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold. <i>European Journal of Medicinal Chemistry</i> , 2018, 148, 453-464.	2.6	5
150	Rational modifications on a benzylidene-acrylohydrazide antiviral scaffold, synthesis and evaluation of bioactivity against Chikungunya virus. <i>European Journal of Medicinal Chemistry</i> , 2018, 149, 56-68.	2.6	20
151	Structurally Diverse Diterpenoids from <i>Sandwithia guyanensis</i> . <i>Journal of Natural Products</i> , 2018, 81, 901-912.	1.5	18
152	Interferon lambda (IFN- λ) efficiently blocks norovirus transmission in a mouse model. <i>Antiviral Research</i> , 2018, 149, 7-15.	1.9	24
153	Synthesis of Enantiomerically Pure 1 α ,2 α -cis-dideoxy, -dideoxydi α dehydro, -ribo and -deoxy Carbocyclic Nucleoside Analogues. <i>Synthesis</i> , 2018, 50, 2266-2280.	1.2	4
154	Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. <i>Journal of Clinical Virology</i> , 2018, 101, 11-17.	1.6	161
155	Inhibition of the Replication of Different Strains of Chikungunya Virus by 3-Aryl-[1,2,3]triazolo[4,5- <i>d</i>]pyrimidin-7(6 <i>H</i>)-ones. <i>ACS Infectious Diseases</i> , 2018, 4, 605-619.	1.8	18
156	A reassessment of mycophenolic acid as a lead compound for the development of inhibitors of chikungunya virus replication. <i>Tetrahedron</i> , 2018, 74, 1294-1306.	1.0	5
157	Design, synthesis and evaluation against Chikungunya virus of novel small-molecule antiviral agents. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 869-874.	1.4	16
158	Hepatitis E virus replication and interferonresponse in human placental-derived cells. <i>Journal of Hepatology</i> , 2018, 68, S786.	1.8	0
159	Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1823-1829.	1.3	18
160	Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. <i>Antiviral Research</i> , 2018, 153, 85-94.	1.9	295
161	Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection. <i>Antiviral Research</i> , 2018, 149, 113-117.	1.9	30
162	New Models to Study Hepatitis E Virus Replication and Particular Characteristics of Infection: The Needle Hides in the Hay Stack. <i>Gastroenterology</i> , 2018, 154, 20-22.	0.6	1

#	ARTICLE	IF	CITATIONS
163	Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model. <i>Antiviral Research</i> , 2018, 149, 150-153.	1.9	0
164	A yellow feverâ€Ž Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. <i>Npj Vaccines</i> , 2018, 3, 56.	2.9	41
165	Human stem cell-derived hepatocyte-like cells support Zika virus replication and provide a relevant model to assess the efficacy of potential antivirals. <i>PLoS ONE</i> , 2018, 13, e0209097.	1.1	15
166	CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer. <i>Experimental Cell Research</i> , 2018, 372, 168-177.	1.2	41
167	A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. <i>Cell Host and Microbe</i> , 2018, 24, 487-499.e5.	5.1	46
168	Favipiravir inhibits in vitro Usutu virus replication and delays disease progression in an infection model in mice. <i>Antiviral Research</i> , 2018, 160, 137-142.	1.9	27
169	Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon- β . <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 469-479.	0.5	11
170	PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3375-3384.	1.3	4
171	Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8402-8416.	2.9	26
172	Antiviral effect of the nucleoside analogue cidofovir in the context of sexual transmission of a gammaherpesvirus in mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2095-2103.	1.3	2
173	Antiplasmodial, anti-chikungunya virus and antioxidant activities of 64 endemic plants from the Mascarene Islands. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 622-628.	1.1	32
174	A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, Rotavirus, and Sapovirus-Induced Diarrhea. <i>Journal of Infectious Diseases</i> , 2018, 218, 1753-1758.	1.9	23
175	Assessing medicinal plants traditionally used in the Chirang Reserve Forest, Northeast India for antimicrobial activity. <i>Journal of Ethnopharmacology</i> , 2018, 225, 220-233.	2.0	33
176	HCV-induced EGFR-ERK signaling promotes a pro-inflammatory and pro-angiogenic signature contributing to liver cancer pathogenesis. <i>Biochemical Pharmacology</i> , 2018, 155, 305-315.	2.0	25
177	Identification of Broadâ€Ž Spectrum Dengue/Zika Virus Replication Inhibitors by Functionalization of Quinoline and 2,6â€Ž Diaminopurine Scaffolds. <i>ChemMedChem</i> , 2018, 13, 1371-1376.	1.6	13
178	Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8390-8401.	2.9	43
179	Assessing the Efficacy of Small Molecule Inhibitors in a Mouse Model of Persistent Norovirus Infection. <i>Bio-protocol</i> , 2018, 8, e2831.	0.2	1
180	Shape-based virtual screening, synthesis and evaluation of novel pyrrolone derivatives as antiviral agents against HCV. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 936-940.	1.0	11

#	ARTICLE	IF	CITATIONS
181	Biological or pharmacological activation of protein kinase C alpha constrains hepatitis E virus replication. <i>Antiviral Research</i> , 2017, 140, 1-12.	1.9	13
182	A novel kindred with inherited STAT2 deficiency and severe viral illness. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1995-1997.e9.	1.5	71
183	Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. <i>Antiviral Research</i> , 2017, 140, 37-44.	1.9	43
184	Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1400-1416.	2.9	17
185	Glutathione is a highly efficient thermostabilizer of poliovirus Sabin strains. <i>Vaccine</i> , 2017, 35, 1370-1372.	1.7	8
186	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. <i>Gut</i> , 2017, 66, 920-929.	6.1	113
187	Chikungunya virus infections: time to act, time to treat. <i>Current Opinion in Virology</i> , 2017, 24, 25-30.	2.6	39
188	Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice. <i>Journal of Hepatology</i> , 2017, 66, S246.	1.8	0
189	Antiviral activity of [1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones against chikungunya virus targeting the viral capping nsP1. <i>Antiviral Research</i> , 2017, 144, 216-222.	1.9	44
190	Antiviral Agents Towards Chikungunya Virus: Structures, Syntheses, and Isolation from Natural Sources. , 2017, , 251-274.		1
191	Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase. <i>Journal of Virology</i> , 2017, 91, .	1.5	62
192	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 139-142.	1.0	27
193	Structure-activity relationship studies on a Trp dendrimer with dual activities against HIV and enterovirus A71. Modifications on the amino acid. <i>Antiviral Research</i> , 2017, 139, 32-40.	1.9	17
194	Protein kinases C as potential host targets for the inhibition of chikungunya virus replication. <i>Antiviral Research</i> , 2017, 139, 79-87.	1.9	20
195	Heterocyclic pharmacology of new rhinovirus antiviral agents: A combined computational and experimental study. <i>European Journal of Medicinal Chemistry</i> , 2017, 140, 528-541.	2.6	11
196	New class of early-stage enterovirus inhibitors with a novel mechanism of action. <i>Antiviral Research</i> , 2017, 147, 67-74.	1.9	14
197	Bioactive Natural Products Prioritization Using Massive Multi-informational Molecular Networks. <i>ACS Chemical Biology</i> , 2017, 12, 2644-2651.	1.6	112
198	A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5472-5492.	2.9	24

#	ARTICLE	IF	CITATIONS
199	Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals. <i>Antiviral Research</i> , 2017, 145, 82-86.	1.9	41
200	Isolation of Premyrsinane, Myrsinane, and Tiglane Diterpenoids from <i>Euphorbia pithyusa</i> Using a Chikungunya Virus Cell-Based Assay and Analogue Annotation by Molecular Networking. <i>Journal of Natural Products</i> , 2017, 80, 2051-2059.	1.5	37
201	In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase. <i>European Journal of Medicinal Chemistry</i> , 2017, 125, 1115-1131.	2.6	18
202	Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery. <i>Biochemical Pharmacology</i> , 2017, 127, 1-12.	2.0	66
203	Aminopurine and aminoquinazoline scaffolds for development of potential dengue virus inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 101-109.	2.6	27
204	Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 327-337.	1.4	34
205	ZikaPLAN: Zika Preparedness Latin American Network. <i>Global Health Action</i> , 2017, 10, 1398485.	0.7	25
206	Antimicrobial, Anthelmintic, and Antiviral Activity of Plants Traditionally Used for Treating Infectious Disease in the Similipal Biosphere Reserve, Odisha, India. <i>Frontiers in Pharmacology</i> , 2017, 8, 658.	1.6	78
207	Fluorination of Naturally Occurring N6-Benzyladenosine Remarkably Increased Its Antiviral Activity and Selectivity. <i>Molecules</i> , 2017, 22, 1219.	1.7	16
208	Upregulation of sodium taurocholate cotransporter polypeptide during hepatogenic differentiation of umbilical cord matrix mesenchymal stem cells facilitates hepatitis B entry. <i>Stem Cell Research and Therapy</i> , 2017, 8, 204.	2.4	6
209	Novel therapeutic approaches to simultaneously target rhinovirus infection and asthma/COPD pathogenesis. <i>F1000Research</i> , 2017, 6, 1860.	0.8	14
210	Tiyozolidinonlar, a-tiyozolidinonlar ve 4-tiyazolidinonlar'ın sentezi, karakterizasyonu ve antikanser ve antiviral etkilerinin değerlendirilmesi. <i>Marmara Pharmaceutical Journal</i> , 2017, 21, 371-371.	0.5	15
211	In silico development of a novel putative inhibitor of the 3C protease of Coxsackievirus B3 with a benzene sulfonamide skeleton. <i>Journal of Pharmaceutical Chemistry</i> , 2017, 4, 25-34.	0.2	1
212	In vitro Assay to Assess Efficacy of Potential Antiviral Compounds against Enterovirus D68. <i>Bio-protocol</i> , 2017, 7, e2183.	0.2	2
213	Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus. <i>Molecules</i> , 2016, 21, 228.	1.7	24
214	A Refined Guinea Pig Model of Foot-and-Mouth Disease Virus Infection for Assessing the Efficacy of Antiviral Compounds. <i>Transboundary and Emerging Diseases</i> , 2016, 63, e205-e212.	1.3	12
215	Optimization of a Class of Tryptophan Dendrimers That Inhibit HIV Replication Leads to a Selective, Specific, and Low-Nanomolar Inhibitor of Clinical Isolates of Enterovirus A71. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5064-5067.	1.4	18
216	Towards antiviral therapies for treating dengue virus infections. <i>Current Opinion in Pharmacology</i> , 2016, 30, 1-7.	1.7	49

#	ARTICLE	IF	CITATIONS
217	Extrahepatic replication and infection of hepatitis E virus in neuronal-derived cells. <i>Journal of Viral Hepatitis</i> , 2016, 23, 512-521.	1.0	104
218	A rat model for hepatitis E virus. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 1203-1210.	1.2	23
219	3-(imidazo[1,2-a:5,4-b]dipyridin-2-yl)aniline inhibits pestivirus replication by targeting a hot spot drug binding pocket in the RNA-dependent RNA polymerase. <i>Antiviral Research</i> , 2016, 129, 99-103.	1.9	8
220	Synthetic strategy and antiviral evaluation of diamide containing heterocycles targeting dengue and yellow fever virus. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 158-168.	2.6	34
221	Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2603-2620.	1.4	6
222	Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. <i>Journal of Hepatology</i> , 2016, 65, 499-508.	1.8	99
223	Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses <i>In Vitro</i> and against Human Metapneumovirus in Hamsters. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4620-4629.	1.4	39
224	Identification and Analysis of Antiviral Compounds Against Poliovirus. <i>Methods in Molecular Biology</i> , 2016, 1387, 325-338.	0.4	0
225	Zika and Other Emerging Viruses: Aiming at the Right Target. <i>Cell Host and Microbe</i> , 2016, 20, 420-422.	5.1	8
226	PKCA/AP-1 Drives Transcription of Interferon-Stimulated Genes and Mediates Cell-Autonomous Defense against Hepatitis E Virus. <i>Journal of Hepatology</i> , 2016, 64, S529.	1.8	0
227	Norovirus genetic diversity and evolution: implications for antiviral therapy. <i>Current Opinion in Virology</i> , 2016, 20, 92-98.	2.6	17
228	Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism. <i>Biochemical Pharmacology</i> , 2016, 120, 15-21.	2.0	11
229	Toward antiviral therapy/prophylaxis for rhinovirus-induced exacerbations of chronic obstructive pulmonary disease: challenges, opportunities, and strategies. <i>Reviews in Medical Virology</i> , 2016, 26, 21-33.	3.9	22
230	Hydantoin: The mechanism of its <i>in vitro</i> anti-enterovirus activity revisited. <i>Antiviral Research</i> , 2016, 133, 106-109.	1.9	10
231	Zika Virus Replicons for Drug Discovery. <i>EBioMedicine</i> , 2016, 12, 156-160.	2.7	77
232	Viral Macro Domains Reverse Protein ADP-Ribosylation. <i>Journal of Virology</i> , 2016, 90, 8478-8486.	1.5	140
233	Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 31-47.	2.6	26
234	The viral capping enzyme nsP1: a novel target for the inhibition of chikungunya virus infection. <i>Scientific Reports</i> , 2016, 6, 31819.	1.6	88

#	ARTICLE	IF	CITATIONS
235	Antiviral Strategies Against Chikungunya Virus. <i>Methods in Molecular Biology</i> , 2016, 1426, 243-253.	0.4	24
236	Reply. <i>Gastroenterology</i> , 2016, 150, 1690-1691.	0.6	0
237	Post-exposure antiviral treatment of norovirus infections effectively protects against diarrhea and reduces virus shedding in the stool in a mortality mouse model. <i>Antiviral Research</i> , 2016, 132, 76-84.	1.9	14
238	Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model. <i>Antiviral Research</i> , 2016, 132, 46-49.	1.9	54
239	9-Norbornyl-6-chloropurine (NCP) induces cell death through GSH depletion-associated ER stress and mitochondrial dysfunction. <i>Free Radical Biology and Medicine</i> , 2016, 97, 223-235.	1.3	20
240	Exploring the importance of zinc binding and steric/hydrophobic factors in novel HCV replication inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1196-1199.	1.0	3
241	Modification of the length and structure of the linker of N6-benzyladenosine modulates its selective antiviral activity against enterovirus 71. <i>European Journal of Medicinal Chemistry</i> , 2016, 111, 84-94.	2.6	29
242	VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 453-462.	2.6	6
243	Simplified Bryostatin Analogues Protect Cells from Chikungunya Virus-Induced Cell Death. <i>Journal of Natural Products</i> , 2016, 79, 675-679.	1.5	16
244	Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway. <i>Journal of Natural Products</i> , 2016, 79, 680-684.	1.5	28
245	Treatment with a Nucleoside Polymerase Inhibitor Reduces Shedding of Murine Norovirus in Stool to Undetectable Levels without Emergence of Drug-Resistant Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1907-1911.	1.4	13
246	Update on hepatitis E virology: Implications for clinical practice. <i>Journal of Hepatology</i> , 2016, 65, 200-212.	1.8	165
247	Stem cell-derived hepatocytes: A novel model for hepatitis E virus replication. <i>Journal of Hepatology</i> , 2016, 64, 565-573.	1.8	51
248	Assessment of the activity of directly acting antivirals and other products against different genotypes of hepatitis C virus prevalent in resource-poor countries. <i>Antiviral Research</i> , 2016, 125, 43-45.	1.9	2
249	Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin. <i>Gastroenterology</i> , 2016, 150, 82-85.e4.	0.6	175
250	Biosafety standards for working with Crimean-Congo hemorrhagic fever virus. <i>Journal of General Virology</i> , 2016, 97, 2799-2808.	1.3	39
251	The Viral Polymerase Inhibitor 7-Deaza-2â€™-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004695.	1.3	250
252	New Conjugated Compounds Coming On Stream against Hepatitis C Virus. <i>SM Journal of Hepatitis Research and Treatment</i> , 2016, 2, 1-4.	0.0	2

#	ARTICLE	IF	CITATIONS
253	Flaviviral NS4b, chameleon and jackal in the NS5A box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. <i>Reviews in Medical Virology</i> , 2015, 25, 205-223.	3.9	86
254	P209: Near full-length hepatitis E virus genome sequencing analysis in a chronically infected patient following ribavirin treatment failure. <i>Journal of Viral Hepatitis</i> , 2015, 22, 124-125.	1.0	2
255	Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 155-160.	0.3	1
256	The future of antivirals. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 596-602.	1.3	56
257	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4964-4975.	2.9	52
258	Bicyclic and Tricyclic "Expanded" Nucleobase Analogues of Sofosbuvir: New Scaffolds for Hepatitis C Therapies. <i>ACS Infectious Diseases</i> , 2015, 1, 357-366.	1.8	12
259	Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2923-2926.	1.0	70
260	Understanding the molecular mechanism of host-based statin resistance in hepatitis C virus replicon containing cells. <i>Biochemical Pharmacology</i> , 2015, 96, 190-201.	2.0	2
261	Broad-range inhibition of enterovirus replication by OSW-1, a natural compound targeting OSBP. <i>Antiviral Research</i> , 2015, 117, 110-114.	1.9	59
262	In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses. <i>Virology Journal</i> , 2015, 12, 106.	1.4	28
263	Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 190-197.	1.3	31
264	Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection. <i>Chemistry and Biology</i> , 2015, 22, 285-292.	6.2	32
265	Linear and branched alkyl-esters and amides of gallic acid and other (mono-, di- and tri-) hydroxy benzoyl derivatives as promising anti-HCV inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 656-671.	2.6	36
266	Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein. <i>Cell Reports</i> , 2015, 10, 600-615.	2.9	201
267	Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. <i>Gut</i> , 2015, 64, 483-494.	6.1	83
268	Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1747-1752.	1.0	34
269	The microRNA-221/222 cluster balances the antiviral and inflammatory response in viral myocarditis. <i>European Heart Journal</i> , 2015, 36, 2909-2919.	1.0	95
270	P0692 : PKC/AP-1 signaling drives transcription of interferon-stimulated genes and exerts potent antiviral activity against hepatitis C and E viruses. <i>Journal of Hepatology</i> , 2015, 62, S581-S582.	1.8	0

#	ARTICLE	IF	CITATIONS
271	In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance. <i>Antiviral Research</i> , 2015, 120, 112-121.	1.9	5
272	Molecular Chaperone Hsp90 Is a Therapeutic Target for Noroviruses. <i>Journal of Virology</i> , 2015, 89, 6352-6363.	1.5	51
273	The RNA Template Channel of the RNA-Dependent RNA Polymerase as a Target for Development of Antiviral Therapy of Multiple Genera within a Virus Family. <i>PLoS Pathogens</i> , 2015, 11, e1004733.	2.1	55
274	Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. <i>Antiviral Chemistry and Chemotherapy</i> , 2015, 24, 56-61.	0.3	9
275	LC-MS2-Based dereplication of Euphorbia extracts with anti-Chikungunya virus activity. <i>FASEB J</i> , 2015, 105, 202-209.	1.1	37
276	NMR-based conformational analysis of 2,6-disubstituted uridines and antiviral evaluation of new phosphoramidate prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5809-5815.	1.4	5
277	Towards antivirals against chikungunya virus. <i>Antiviral Research</i> , 2015, 121, 59-68.	1.9	84
278	Tonantzitlolones from <i>Stillingia lineata</i> ssp. <i>lineata</i> as potential inhibitors of chikungunya virus. <i>Phytochemistry Letters</i> , 2015, 12, 313-319.	0.6	14
279	Antiviral Activity of Diterpene Esters on Chikungunya Virus and HIV Replication. <i>Journal of Natural Products</i> , 2015, 78, 1277-1283.	1.5	62
280	Antiviral Activity of Flexibilane and Tiglane Diterpenoids from <i>Stillingia lineata</i> . <i>Journal of Natural Products</i> , 2015, 78, 1119-1128.	1.5	39
281	Benzouracil-coumarin-arene conjugates as inhibiting agents for chikungunya virus. <i>Antiviral Research</i> , 2015, 118, 103-109.	1.9	35
282	Reaching beyond HIV/HCV: nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus. <i>RSC Advances</i> , 2015, 5, 85938-85949.	1.7	21
283	Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7782-7785.	1.4	54
284	The Enterovirus 3C Protease Inhibitor SG85 Efficiently Blocks Rhinovirus Replication and Is Not Cross-Resistant with Rupintrivir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5814-5818.	1.4	18
285	ID: 146. <i>Cytokine</i> , 2015, 76, 94.	1.4	1
286	New 1-phenyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides inhibit hepatitis C virus replication via suppression of cyclooxygenase-2. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 497-506.	2.6	25
287	Norbornane-based nucleoside and nucleotide analogues locked in North conformation. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 184-191.	1.4	16
288	Chemical modification of the plant isoprenoid cytokinin N6-isopentenyladenosine yields a selective inhibitor of human enterovirus 71 replication. <i>European Journal of Medicinal Chemistry</i> , 2015, 90, 406-413.	2.6	23

#	ARTICLE	IF	CITATIONS
289	Antiviral treatment of feline immunodeficiency virus-infected cats with (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine. <i>Journal of Feline Medicine and Surgery</i> , 2015, 17, 79-86.	0.6	5
290	Structure Elucidation of Coxsackievirus A16 in Complex with GPP3 Informs a Systematic Review of Highly Potent Capsid Binders to Enteroviruses. <i>PLoS Pathogens</i> , 2015, 11, e1005165.	2.1	20
291	Trigocherrierin A, a Potent Inhibitor of Chikungunya Virus Replication. <i>Molecules</i> , 2014, 19, 3617-3627.	1.7	44
292	Proof of Concept for the Inhibition of Foot-and-Mouth Disease Virus Replication by the Anti-Viral Drug 2-Deoxy-2-(2-methylcytidine) in Severe Combined Immunodeficient Mice. <i>Transboundary and Emerging Diseases</i> , 2014, 61, e89-e91.	1.3	19
293	The Enterovirus Protease Inhibitor Rupintrivir Exerts Cross-Genotypic Anti-Norovirus Activity and Clears Cells from the Norovirus Replicon. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4675-4681.	1.4	45
294	Complete Genome Sequence of a Rat Hepatitis E Virus Strain Isolated in the United States. <i>Genome Announcements</i> , 2014, 2, .	0.8	4
295	Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis. <i>PLoS Pathogens</i> , 2014, 10, e1004039.	2.1	37
296	Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4875-4884.	1.4	611
297	Are statins a viable option for the treatment of infections with the hepatitis C virus?. <i>Antiviral Research</i> , 2014, 105, 92-99.	1.9	12
298	O118 A MUTATION IN THE HEPATITIS E VIRUS POLYMERASE ASSOCIATED WITH RIBAVIRIN TREATMENT FAILURE HAS A REPLICATION ADVANTAGE IN VITRO. <i>Journal of Hepatology</i> , 2014, 60, S49-S50.	1.8	0
299	Substituted 2,6-bis(benzimidazol-2-yl)pyridines: A novel chemical class of pestivirus inhibitors that targets a hot spot for inhibition of pestivirus replication in the RNA-dependent RNA polymerase. <i>Antiviral Research</i> , 2014, 106, 71-79.	1.9	20
300	From norbornane-based nucleotide analogs locked in South conformation to novel inhibitors of feline herpes virus. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 2974-2983.	1.4	15
301	Synthesis, biological activity and structure-activity relationship of 4,5-dimethoxybenzene derivatives inhibitor of rhinovirus 14 infection. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 445-459.	2.6	15
302	Identification of [1,2,3]Triazolo[4,5-d]pyrimidin-7(6H)-ones as Novel Inhibitors of Chikungunya Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4000-4008.	2.9	60
303	New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3247-3262.	2.9	35
304	The Versatile Nature of the 6-Aminoquinolone Scaffold: Identification of Submicromolar Hepatitis C Virus NS5B Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 1952-1963.	2.9	43
305	Antiviral strategies for hepatitis E virus. <i>Antiviral Research</i> , 2014, 102, 106-118.	1.9	39
306	Application of a cell-based protease assay for testing inhibitors of picornavirus 3C proteases. <i>Antiviral Research</i> , 2014, 103, 17-24.	1.9	17

#	ARTICLE	IF	CITATIONS
307	Ribavirin Inhibits <i>In Vitro</i> Hepatitis E Virus Replication through Depletion of Cellular GTP Pools and Is Moderately Synergistic with Alpha Interferon. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 267-273.	1.4	126
308	A Mutation in the Hepatitis E Virus RNA Polymerase Promotes Its Replication and Associates With Ribavirin Treatment Failure in Organ Transplant Recipients. <i>Gastroenterology</i> , 2014, 147, 1008-1011.e7.	0.6	171
309	Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6014-6025.	1.4	43
310	A thiazepino[4,5-a]benzimidazole derivative hampers the RNA replication of Eurasian serotypes of foot-and-mouth disease virus. <i>Biochemical and Biophysical Research Communications</i> , 2014, 455, 378-381.	1.0	5
311	Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2770-2784.	1.3	187
312	H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. <i>Antiviral Research</i> , 2014, 110, 1-9.	1.9	12
313	A novel benzonitrile analogue inhibits rhinovirus replication. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2723-2732.	1.3	27
314	The Capsid Binder Vapendavir and the Novel Protease Inhibitor SC85 Inhibit Enterovirus 71 Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6990-6992.	1.4	60
315	Synthesis of Novel Purine-Based Coxsackievirus Inhibitors Bearing Polycyclic Substituents at the N ⁹ Position. <i>Archiv Der Pharmazie</i> , 2014, 347, 478-485.	2.1	5
316	Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 529-539.	2.6	57
317	In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks. <i>Antiviral Research</i> , 2014, 105, 59-63.	1.9	9
318	Calcineurin Inhibitors Stimulate and Mycophenolic Acid Inhibits Replication of Hepatitis E Virus. <i>Gastroenterology</i> , 2014, 146, 1775-1783.	0.6	158
319	P212 STEM CELL-DERIVED HEPATOCYTES AS A NOVEL IN VITRO MODEL TO STUDY HEPATOTROPIC VIRUSES. <i>Journal of Hepatology</i> , 2014, 60, S136.	1.8	0
320	In search of Flavivirus inhibitors part 2: Tritylated, diphenylmethylated and other alkylated nucleoside analogues. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 98-109.	2.6	25
321	Fitness and Virulence of a Coxsackievirus Mutant That Can Circumnavigate the Need for Phosphatidylinositol 4-Kinase Class III Beta. <i>Journal of Virology</i> , 2014, 88, 3048-3051.	1.5	7
322	Jatrophane Diterpenes as Inhibitors of Chikungunya Virus Replication: Structure-Activity Relationship and Discovery of a Potent Lead. <i>Journal of Natural Products</i> , 2014, 77, 1505-1512.	1.5	67
323	Tigliane diterpenes from <i>Croton mauritianus</i> as inhibitors of chikungunya virus replication. <i>FÄ-toterapÄ-t</i> , 2014, 97, 87-91.	1.1	50
324	Norovirus: Targets and tools in antiviral drug discovery. <i>Biochemical Pharmacology</i> , 2014, 91, 1-11.	2.0	49

#	ARTICLE	IF	CITATIONS
325	Molecular Biology and Inhibitors of Hepatitis A Virus. <i>Medicinal Research Reviews</i> , 2014, 34, 895-917.	5.0	31
326	mTOR-inhibitors may aggravate chronic hepatitis E. <i>Journal of Hepatology</i> , 2014, 61, 720-722.	1.8	5
327	Infectious Virus Yield Assay for Hepatitis E Virus. <i>Bio-protocol</i> , 2014, 4, .	0.2	1
328	Luminescence-based Antiviral Assay for Hepatitis E Virus. <i>Bio-protocol</i> , 2014, 4, .	0.2	1
329	Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. <i>Antiviral Research</i> , 2013, 99, 165-171.	1.9	86
330	Intra-host variation structure of classical swine fever virus NS5B in relation to antiviral therapy. <i>Antiviral Research</i> , 2013, 98, 266-272.	1.9	5
331	The potential of antiviral agents to control classical swine fever: A modelling study. <i>Antiviral Research</i> , 2013, 99, 245-250.	1.9	16
332	Simple and inexpensive three-step rapid amplification of cDNA 5' ends using 5' phosphorylated primers. <i>Analytical Biochemistry</i> , 2013, 434, 1-3.	1.1	17
333	Erratum to "Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus" [<i>J Hepatol</i> 2012;57:246-251]. <i>Journal of Hepatology</i> , 2013, 58, 199-200.	1.8	0
334	Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative. <i>Antiviral Research</i> , 2013, 100, 238-245.	1.9	15
335	Structure-Based Discovery of Pyrazolobenzothiazine Derivatives As Inhibitors of Hepatitis C Virus Replication. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2270-2282.	2.9	40
336	Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B virus infection. <i>Hepatology</i> , 2013, 57, 59-69.	3.6	24
337	Laboratory validation of a lateral flow device for the detection of CyHV-3 antigens in gill swabs. <i>Journal of Virological Methods</i> , 2013, 193, 679-682.	1.0	13
338	Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication. <i>Antiviral Research</i> , 2013, 98, 325-331.	1.9	12
339	1194 SYNERGISTIC COMBINATIONS OF ENTRY INHIBITORS WITH DACLATASVIR OR SOFOSBUVIR FOR PREVENTION AND TREATMENT OF CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2013, 58, S486.	1.8	0
340	Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of hepatitis E virus replication. <i>Antiviral Research</i> , 2013, 100, 98-101.	1.9	14
341	Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 290-298.	2.6	61
342	Hepatitis C Virus-Specific Directly Acting Antiviral Drugs. <i>Current Topics in Microbiology and Immunology</i> , 2013, 369, 289-320.	0.7	27

#	ARTICLE	IF	CITATIONS
343	Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. <i>Antiviral Research</i> , 2013, 98, 12-18.	1.9	87
344	Intervention strategies for emerging viruses: use of antivirals. <i>Current Opinion in Virology</i> , 2013, 3, 217-224.	2.6	37
345	9-[2-(R)-(Phosphonomethoxy)propyl]-2,6-diaminopurine (R)-PMPDAP and its prodrugs: Optimized preparation, including identification of by-products formed, and antiviral evaluation in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1199-1208.	1.4	13
346	In search of flavivirus inhibitors: Evaluation of different tritylated nucleoside analogues. <i>European Journal of Medicinal Chemistry</i> , 2013, 65, 249-255.	2.6	28
347	3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and analogues, novel Flaviviridae inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 448-463.	2.6	42
348	3- <i>O</i> ,5- <i>O</i> -Di- <i>O</i> -trityluridine inhibits in vitro flavivirus replication. <i>Antiviral Research</i> , 2013, 98, 242-247.	1.9	28
349	Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 585-589.	1.3	36
350	Exploration of the <i>in vitro</i> Antiviral Activity of a Series of New Pyrimidine Analogues on the Replication of HIV and HCV. <i>Antiviral Chemistry and Chemotherapy</i> , 2013, 23, 103-112.	0.3	8
351	Selecting and Characterizing Drug-Resistant Hepatitis C Virus Replicon. <i>Methods in Molecular Biology</i> , 2013, 1030, 93-103.	0.4	3
352	The Viral Polymerase Inhibitor 2'-Methylcytidine Inhibits Norwalk Virus Replication and Protects against Norovirus-Induced Diarrhea and Mortality in a Mouse Model. <i>Journal of Virology</i> , 2013, 87, 11798-11805.	1.5	85
353	A Novel, Broad-Spectrum Inhibitor of Enterovirus Replication That Targets Host Cell Factor Phosphatidylinositol 4-Kinase III β . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4971-4981.	1.4	96
354	Selective Serotonin Reuptake Inhibitor Fluoxetine Inhibits Replication of Human Enteroviruses B and D by Targeting Viral Protein 2C. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1952-1956.	1.4	81
355	3C Protease of Enterovirus 68: Structure-Based Design of Michael Acceptor Inhibitors and Their Broad-Spectrum Antiviral Effects against Picornaviruses. <i>Journal of Virology</i> , 2013, 87, 4339-4351.	1.5	91
356	Phosphatidylinositol 4-Kinase III β Is Essential for Replication of Human Rhinovirus and Its Inhibition Causes a Lethal Phenotype <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3358-3368.	1.4	72
357	The microRNA 221/222 cluster controls CVB3-induced myocarditis: could tiny microRNAs explain adverse inflammation in the heart?. <i>European Heart Journal</i> , 2013, 34, 5866-5866.	1.0	1
358	The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination. <i>Hepatology</i> , 2013, 57, 492-504.	3.6	66
359	Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication. <i>PLoS ONE</i> , 2013, 8, e81783.	1.1	51
360	124 HEPATOCYTES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS PERMIT COMPLETE REPLICATION OF THE HEPATITIS C VIRUS. <i>Journal of Hepatology</i> , 2012, 56, S54-S55.	1.8	0

#	ARTICLE	IF	CITATIONS
361	Classical swine fever outbreak containment using antiviral supplementation: A potential alternative to emergency vaccination and stamping-out. <i>Preventive Veterinary Medicine</i> , 2012, 106, 34-41.	0.7	16
362	Prostratin and 12-O-Tetradecanoylphorbol 13-Acetate Are Potent and Selective Inhibitors of Chikungunya Virus Replication. <i>Journal of Natural Products</i> , 2012, 75, 2183-2187.	1.5	87
363	705 Stimulation of Angiogenesis by Hepatitis C Virus (HCV) Non-structural Proteins. <i>European Journal of Cancer</i> , 2012, 48, S167.	1.3	0
364	841 BC556, A POTENT, PAN-GENOTYPIC, HIGH BARRIER TO RESISTANCE, SECOND GENERATION CYCLOPHILIN INHIBITOR FOR TREATMENT OF CHRONIC HCV INFECTION. <i>Journal of Hepatology</i> , 2012, 56, S328.	1.8	1
365	Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2327-2337.	1.3	12
366	Coxsackievirus mutants that can bypass host factor PI4KIII β and the need for high levels of PI4P lipids for replication. <i>Cell Research</i> , 2012, 22, 1576-1592.	5.7	110
367	In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. <i>Journal of Hepatology</i> , 2012, 56, 41-48.	1.8	16
368	Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. <i>Journal of Hepatology</i> , 2012, 57, 246-251.	1.8	90
369	Favipiravir (T-705) inhibits in vitro norovirus replication. <i>Biochemical and Biophysical Research Communications</i> , 2012, 424, 777-780.	1.0	122
370	Crucial role of the N-glycans on the viral E-envelope glycoprotein in DC-SIGN-mediated dengue virus infection. <i>Antiviral Research</i> , 2012, 96, 280-287.	1.9	29
371	Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 796-800.	1.0	59
372	The role of phosphatidylinositol 4-kinases and phosphatidylinositol 4-phosphate during viral replication. <i>Biochemical Pharmacology</i> , 2012, 84, 1400-1408.	2.0	61
373	Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection. <i>MedChemComm</i> , 2012, 3, 944-949.	3.5	23
374	An Analogue of the Antibiotic Teicoplanin Prevents Flavivirus Entry In Vitro. <i>PLoS ONE</i> , 2012, 7, e37244.	1.1	43
375	Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1884-1894.	1.3	329
376	Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. <i>Antiviral Research</i> , 2012, 93, 30-38.	1.9	19
377	Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. <i>Antiviral Research</i> , 2012, 93, 160-166.	1.9	16
378	Evaluation of the antiviral activity of (1 <i>S</i> ,2 <i>R</i>)-9-[[1 <i>S</i> ,2 <i>S</i> -bis(hydroxymethyl)cycloprop-1 <i>yl</i>]methyl]guanine (A-5021) against equine herpesvirus type 1 in cell monolayers and equine nasal mucosal explants. <i>Antiviral Research</i> , 2012, 93, 234-238.	1.9	10

#	ARTICLE	IF	CITATIONS
379	Efficient synthesis and anti-enteroviral activity of 9-arylpurines. <i>European Journal of Medicinal Chemistry</i> , 2012, 49, 279-288.	2.6	21
380	Combating enterovirus replication: State-of-the-art on antiviral research. <i>Biochemical Pharmacology</i> , 2012, 83, 185-192.	2.0	133
381	Pyridobenzothiazole derivatives as new chemotype targeting the HCV NS5B polymerase. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 866-876.	1.4	41
382	Novel 1,2,4-triazole and imidazole derivatives of l-ascorbic and imino-ascorbic acid: Synthesis, anti-HCV and antitumor activity evaluations. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3675-3685.	1.4	70
383	Novel substituted 9-norbornylpurines and their activities against RNA viruses. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1963-1968.	1.0	7
384	A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. <i>Journal of Virological Methods</i> , 2012, 183, 176-179.	1.0	30
385	Synthesis of novel azanorbornylpurine derivatives. <i>Tetrahedron</i> , 2012, 68, 1286-1298.	1.0	13
386	Synthesis of novel thienonorbornylpurine derivatives. <i>Tetrahedron</i> , 2012, 68, 3195-3204.	1.0	5
387	The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function. <i>PLoS ONE</i> , 2012, 7, e39163.	1.1	41
388	Development of New Sulfur-Containing Conjugated Compounds as Anti-HCV Agents. <i>Phosphorus, Sulfur and Silicon and the Related Elements</i> , 2011, 186, 1144-1152.	0.8	6
389	Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. <i>Current Opinion in Virology</i> , 2011, 1, 590-598.	2.6	101
390	Coumarin ³ Purine Ribofuranoside Conjugates as New Agents against Hepatitis C Virus. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 2114-2126.	2.9	112
391	482 IN VITRO COMBINATION THERAPY WITH TEGOBUVIR (GS-9190) IS HIGHLY EFFICIENT IN CURING CELLS FROM HCV REPLICON AND IN DELAYING/PREVENTING THE DEVELOPMENT OF ANTIVIRAL RESISTANCE. <i>Journal of Hepatology</i> , 2011, 54, S197-S198.	1.8	1
392	789 PRECLINICAL CHARACTERIZATION OF NOVEL CYCLOPHILIN INHIBITORS BASED ON THE POLYKETIDE, SANGLIFEHRIN. <i>Journal of Hepatology</i> , 2011, 54, S317.	1.8	0
393	Adefovir serum levels do not differ between responders and nonresponders. <i>Journal of Viral Hepatitis</i> , 2011, 18, e175-8.	1.0	1
394	Diagnostic performance and application of two commercial cell viability assays in foot-and-mouth disease research. <i>Journal of Virological Methods</i> , 2011, 173, 108-114.	1.0	7
395	Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 4281-4288.	2.6	9
396	Picornavirus non-structural proteins as targets for new anti-virals with broad activity. <i>Antiviral Research</i> , 2011, 89, 204-218.	1.9	76

#	ARTICLE	IF	CITATIONS
397	Towards the design of combination therapy for the treatment of enterovirus infections. <i>Antiviral Research</i> , 2011, 90, 213-217.	1.9	45
398	Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. <i>Antiviral Research</i> , 2011, 91, 89-93.	1.9	55
399	The main Hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. <i>Antiviral Research</i> , 2011, 92, 271-276.	1.9	75
400	SAR studies of 9-norbornylpurines as Coxsackievirus B3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 4271-4275.	1.0	20
401	Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4196-4203.	1.4	88
402	Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4103-4113.	1.4	54
403	Conformationally locked nucleoside analogues based on the bridgehead substituted 7-oxonorbornane and their antiviral properties. <i>Collection of Czechoslovak Chemical Communications</i> , 2011, 76, 1549-1566.	1.0	3
404	Preclinical Characterization of Naturally Occurring Polyketide Cyclophilin Inhibitors from the Sanglifehrins Family. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1975-1981.	1.4	53
405	Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1287-1294.	1.3	17
406	Broad Antiviral Activity of Carbohydrate-Binding Agents against the Four Serotypes of Dengue Virus in Monocyte-Derived Dendritic Cells. <i>PLoS ONE</i> , 2011, 6, e21658.	1.1	57
407	Antiviral Activity of Bay 41-4109 on Hepatitis B Virus in Humanized Alb-uPA/SCID Mice. <i>PLoS ONE</i> , 2011, 6, e25096.	1.1	78
408	Synthesis and antiviral activity of an imidazo[1,2-a]pyrrolo[2,3-c]pyridine series against the bovine viral diarrhoea virus. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 2044-2047.	2.6	61
409	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2748-2755.	1.4	29
410	Structure and functionality in flavivirus NS-proteins: Perspectives for drug design. <i>Antiviral Research</i> , 2010, 87, 125-148.	1.9	289
411	Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription. <i>Antiviral Research</i> , 2010, 87, 149-161.	1.9	57
412	Antiviral strategies to control calicivirus infections. <i>Antiviral Research</i> , 2010, 87, 162-178.	1.9	55
413	Highly potent and selective inhibition of bovine viral diarrhoea virus replication by $\hat{1}^3$ -carboline derivatives. <i>Antiviral Research</i> , 2010, 88, 263-268.	1.9	22
414	Development of a Foot-and-Mouth Disease Infection Model in Severe Combined Immunodeficient Mice for the Preliminary Evaluation of Antiviral Drugs. <i>Transboundary and Emerging Diseases</i> , 2010, 57, 430-433.	1.3	5

#	ARTICLE	IF	CITATIONS
415	Reply: Hepatology, 2010, 51, 345-345.	3.6	0
416	Short and efficient access to imidazo[1,2-a]pyrrolo[3,2-c]pyridine derivatives. Tetrahedron Letters, 2010, 51, 6082-6085.	0.7	4
417	Design, synthesis, and biological evaluation of novel coxsackievirus B3 inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 4374-4384.	1.4	31
418	S-Aryltriazole acyclonucleosides: Synthesis and biological evaluation against hepatitis C virus. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3610-3613.	1.0	12
419	Straightforward synthesis of triazoloacyclonucleotide phosphonates as potential HCV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 7365-7368.	1.0	47
420	Synthesis and antiviral activity of boranophosphonate isosteres of AZT and d4T monophosphates. European Journal of Medicinal Chemistry, 2010, 45, 849-856.	2.6	9
421	Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses, 2010, 2, 826-866.	1.5	35
422	DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A. PLoS ONE, 2010, 5, e13687.	1.1	151
423	A Derivate of the Antibiotic Doxorubicin Is a Selective Inhibitor of Dengue and Yellow Fever Virus Replication <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2010, 54, 5269-5280.	1.4	72
424	Differential Effects of the Putative GBF1 Inhibitors Golgicide A and AG1478 on Enterovirus Replication. Journal of Virology, 2010, 84, 7535-7542.	1.5	43
425	Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections. Viruses, 2010, 2, 1279-1305.	1.5	56
426	Tracking the Evolution of Multiple <i>In Vitro</i> Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing. Journal of Virology, 2010, 84, 11124-11133.	1.5	68
427	Synthesis of novel racemic carbocyclic nucleosides derived from 5,6-disubstituted norbornene. Collection of Czechoslovak Chemical Communications, 2010, 75, 1-20.	1.0	9
428	Synthesis of Ester Prodrugs of 9-(<i>S</i>)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-2,6-diaminopurine (HPMPDAP) as Anti-Poxvirus Agents. Journal of Medicinal Chemistry, 2010, 53, 6825-6837.	2.9	30
429	Hepatitis C Virus Infection of Neuroepithelioma Cell Lines. Gastroenterology, 2010, 139, 1365-1374.e2.	0.6	59
430	3'-Deoxy Phosphoramidate Dinucleosides as Improved Inhibitors of Hepatitis C Virus Subgenomic Replicon and NS5B Polymerase Activity. Journal of Medicinal Chemistry, 2010, 53, 6608-6617.	2.9	13
431	9-Aryl purines as a Novel Class of Enterovirus Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 316-324.	2.9	28
432	Replication of not-known-vector flaviviruses in mosquito cells is restricted by intracellular host factors rather than by the viral envelope proteins. Journal of General Virology, 2010, 91, 1693-1697.	1.3	22

#	ARTICLE	IF	CITATIONS
433	Synthesis of novel racemic carbocyclic nucleoside analogues derived from 4,8-dioxatricyclo[4.2.1.0 ^{3,7}]nonane-9-methanol and 4-oxatricyclo[4.3.1.0 ^{3,7}]decane-10-methanol, compounds with activity against Cocksackie viruses. Collection of Czechoslovak Chemical Communications, 2009, 74, 469-485.	1.0	8
434	Proof of concept for the reduction of classical swine fever infection in pigs by a novel viral polymerase inhibitor. Journal of General Virology, 2009, 90, 1335-1342.	1.3	24
435	Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors. Antimicrobial Agents and Chemotherapy, 2009, 53, 967-976.	1.4	121
436	Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307. Antimicrobial Agents and Chemotherapy, 2009, 53, 1850-1857.	1.4	68
437	The reduction of CSFV transmission to untreated pigs by the pestivirus inhibitor BPIP: A proof of concept. Veterinary Microbiology, 2009, 139, 365-368.	0.8	19
438	Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology, 2009, 387, 67-75.	1.1	64
439	A pyrazolotriazolopyrimidinamine inhibitor of bovine viral diarrhea virus replication that targets the viral RNA-dependent RNA polymerase. Antiviral Research, 2009, 82, 141-147.	1.9	26
440	Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step. Antiviral Research, 2009, 84, 48-59.	1.9	19
441	Statins potentiate the <i>in vitro</i> anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology, 2009, 50, 6-16.	3.6	104
442	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology, 2009, 50, 1638-1645.	3.6	108
443	Cu ²⁺ -Mediated Selective N ³ -Arylation of Aminotriazole Acyclonucleosides. Helvetica Chimica Acta, 2009, 92, 1503-1513.	1.0	20
444	Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis. Journal of Pathology, 2009, 217, 633-641.	2.1	14
445	Norbornane as the novel pseudoglycone moiety in nucleosides. Tetrahedron, 2009, 65, 9291-9299.	1.0	16
446	Discovery of a novel HCV helicase inhibitor by a de novo drug design approach. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2935-2937.	1.0	41
447	The phosphoramidate ProTide approach greatly enhances the activity of 2'-C-methylguanosine against hepatitis C virus. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4316-4320.	1.0	43
448	Substituted imidazopyridines as potent inhibitors of HCV replication. Journal of Hepatology, 2009, 50, 999-1009.	1.8	44
449	Structure-Activity Relationship of New Anti-Hepatitis C Virus Agents: Heterobicyclic-Coumarin Conjugates. Journal of Medicinal Chemistry, 2009, 52, 1486-1490.	2.9	199
450	Antiviral Agents Acting as DNA or RNA Chain Terminators. Handbook of Experimental Pharmacology, 2009, , 53-84.	0.9	107

#	ARTICLE	IF	CITATIONS
451	Discovery of Novel Arylethynyltriazole Ribonucleosides with Selective and Effective Antiviral and Antiproliferative Activity. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1144-1155.	2.9	56
452	Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3354-3365.	2.9	54
453	Synthesis and Antiviral Evaluation of 2- ϵ -C-Methyl Analogues of 5-Alkynyl- and 6-Alkylfurano- and Pyrrolo[2,3- <i>d</i>]Pyrimidine Ribonucleosides. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 713-723.	0.4	9
454	88 PARTICULAR IN VITRO ANTI-HCV ACTIVITIES AND RESISTANCE PROFILE OF THE CYCLOPHILIN INHIBITOR DEBIO 025. <i>Journal of Hepatology</i> , 2009, 50, S36.	1.8	13
455	Synthesis of novel carbocyclic nucleoside analogues derived from 7-oxabicyclo[2.2.1]heptane-2-methanol. <i>Collection of Czechoslovak Chemical Communications</i> , 2009, 74, 487-502.	1.0	14
456	Studies of antiviral activity and cytotoxicity of <i>Wrightia tinctoria</i> and <i>Morinda citrifolia</i> . <i>Indian Journal of Pharmaceutical Sciences</i> , 2009, 71, 670.	1.0	19
457	Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. <i>Reviews in Medical Virology</i> , 2008, 18, 19-34.	3.9	67
458	Selective inhibitors of picornavirus replication. <i>Medicinal Research Reviews</i> , 2008, 28, 823-884.	5.0	224
459	Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzotriazoles. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5123-5125.	1.0	13
460	Comparisons of the influenza virus A M2 channel binding affinities, anti-influenza virus potencies and NMDA antagonistic activities of 2-alkyl-2-aminoadamantanes and analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6156-6160.	1.0	28
461	Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3321-3327.	1.0	51
462	Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3433-3437.	1.4	43
463	Phosphoramidate Dinucleosides as Hepatitis C Virus Polymerase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5745-5757.	2.9	12
464	Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis. <i>Virology</i> , 2008, 382, 20-27.	1.1	15
465	Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. <i>Antiviral Research</i> , 2008, 77, 157-162.	1.9	176
466	Imidazo[4,5- <i>c</i>]pyridines inhibit the in vitro replication of the classical swine fever virus and target the viral polymerase. <i>Antiviral Research</i> , 2008, 77, 114-119.	1.9	26
467	International research networks in viral structural proteomics: Again, lessons from SARS. <i>Antiviral Research</i> , 2008, 78, 47-50.	1.9	6
468	FDA perspective on antivirals against biotreats: Communicate early and often. <i>Antiviral Research</i> , 2008, 78, 60-63.	1.9	13

#	ARTICLE	IF	CITATIONS
469	Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses. Antiviral Research, 2008, 78, 79-90.	1.9	77
470	Potential of antiviral therapy and prophylaxis for controlling RNA viral infections of livestock. Antiviral Research, 2008, 78, 170-178.	1.9	42
471	Animal models of highly pathogenic RNA viral infections: Encephalitis viruses. Antiviral Research, 2008, 78, 69-78.	1.9	23
472	Does antiviral therapy have a role in the control of Japanese encephalitis?. Antiviral Research, 2008, 78, 140-149.	1.9	48
473	NIAID resources for developing new therapies for severe viral infections. Antiviral Research, 2008, 78, 51-59.	1.9	10
474	The Southeast Asian Influenza Clinical Research Network: Development and challenges for a new multilateral research endeavor. Antiviral Research, 2008, 78, 64-68.	1.9	17
475	Treatment of yellow fever. Antiviral Research, 2008, 78, 116-124.	1.9	167
476	Treatment of Argentine hemorrhagic fever. Antiviral Research, 2008, 78, 132-139.	1.9	256
477	Treatment of hantavirus pulmonary syndrome. Antiviral Research, 2008, 78, 162-169.	1.9	123
478	The VIZIER project: Preparedness against pathogenic RNA viruses. Antiviral Research, 2008, 78, 37-46.	1.9	26
479	Treatment of Crimean-Congo hemorrhagic fever. Antiviral Research, 2008, 78, 125-131.	1.9	127
480	New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antiviral Research, 2008, 78, 103-115.	1.9	156
481	Highly pathogenic RNA viral infections: Challenges for antiviral research. Antiviral Research, 2008, 78, 1-8.	1.9	40
482	Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Research, 2008, 78, 26-36.	1.9	83
483	R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond. Antiviral Research, 2008, 78, 278-281.	1.9	6
484	Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Research, 2008, 78, 91-102.	1.9	210
485	Molecular strategies to inhibit the replication of RNA viruses. Antiviral Research, 2008, 78, 9-25.	1.9	117
486	Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Research, 2008, 78, 150-161.	1.9	75

#	ARTICLE	IF	CITATIONS
487	A case for developing antiviral drugs against polio. <i>Antiviral Research</i> , 2008, 79, 179-187.	1.9	60
488	Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. <i>Biochemical Pharmacology</i> , 2008, 76, 997-1005.	2.0	21
489	Mouse and Hamster Models for the Study of Therapy against Flavivirus Infections. <i>Novartis Foundation Symposium</i> , 2008, , 218-232.	1.2	2
490	Assessing the Efficacy of Cidofovir against Herpesvirus-Induced Genital Lesions in Goats Using Different Therapeutic Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 4064-4068.	1.4	15
491	The Crystal Structure of Coxsackievirus B3 RNA-Dependent RNA Polymerase in Complex with Its Protein Primer VPg Confirms the Existence of a Second VPg Binding Site on <i>Picornaviridae</i> Polymerases. <i>Journal of Virology</i> , 2008, 82, 9577-9590.	1.5	87
492	The Thiazolobenzimidazole TBZE-029 Inhibits Enterovirus Replication by Targeting a Short Region Immediately Downstream from Motif C in the Nonstructural Protein 2C. <i>Journal of Virology</i> , 2008, 82, 4720-4730.	1.5	71
493	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1302-1317.	1.4	106
494	Synthesis and antiviral activity of novel derivatives of 2'- \hat{A} -C-methylcytidine. <i>Nucleic Acids Symposium Series</i> , 2008, 52, 605-606.	0.3	7
495	Potential Use of Antiviral Agents in Polio Eradication. <i>Emerging Infectious Diseases</i> , 2008, 14, 545-551.	2.0	65
496	<i>In vitro&/i> antiviral activity of some novel isatin derivatives against HCV and SARS-CoV viruses. <i>Indian Journal of Pharmaceutical Sciences</i> , 2008, 70, 91.	1.0	19
497	Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naïve patients is not due to pre-existing drug-resistant mutants. <i>Antiviral Therapy</i> , 2008, 13, 381-8.	0.6	10
498	Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naïve Patients is not due to Pre-Existing Drug-Resistant Mutants. <i>Antiviral Therapy</i> , 2008, 13, 381-388.	0.6	38
499	In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2240-2243.	1.4	43
500	Alkyne-Azide Click Chemistry Mediated Carbanucleosides Synthesis. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2007, 26, 1391-1394.	0.4	18
501	Cross-Metathesis Mediated Synthesis of New Acyclic Nucleoside Phosphonates. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2007, 26, 1399-1402.	0.4	3
502	New Analogs of Acyclovir Substituted at the Side Chain. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2007, 26, 917-920.	0.4	3
503	Evaluation of Hexadecyloxypropyl-9- <i>R</i> -[2-(Phosphonomethoxy)Propyl]-Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 4538-4538.	1.4	3
504	Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D stem-loop structure is not required for replication. <i>Journal of General Virology</i> , 2007, 88, 2361-2361.	1.3	0

#	ARTICLE	IF	CITATIONS
505	Conservation of the pentanucleotide motif at the top of the yellow fever virus 17D 3' stem-loop structure is not required for replication. <i>Journal of General Virology</i> , 2007, 88, 1738-1747.	1.3	19
506	Evaluation of Hexadecyloxypropyl-9- <i>R</i> -[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3505-3509.	1.4	68
507	The Imidazopyrrolopyridine Analogue AG110 Is a Novel, Highly Selective Inhibitor of Pestiviruses That Targets the Viral RNA-Dependent RNA Polymerase at a Hot Spot for Inhibition of Viral Replication. <i>Journal of Virology</i> , 2007, 81, 11046-11053.	1.5	43
508	Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. <i>Trends in Pharmacological Sciences</i> , 2007, 28, 280-285.	4.0	57
509	Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1 <i>H</i> ,3 <i>H</i> -thiazolo[3,4- <i>a</i>]benzimidazoles. <i>Biochemical and Biophysical Research Communications</i> , 2007, 353, 628-632.	1.0	39
510	Ester Prodrugs of Cyclic 1-(<i>S</i>)-[3-Hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: Synthesis and Antiviral Activity. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5765-5772.	2.9	50
511	Antiviral Activity of Triazine Analogues of 1-(<i>S</i>)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine (Cidofovir) and Related Compounds. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 1069-1077.	2.9	79
512	Antiviral 2,5-disubstituted imidazo[4,5- <i>c</i>]pyridines: From anti-pestivirus to anti-hepatitis C virus activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 390-393.	1.0	71
513	Influence of an additional 2-amino substituent of the 1-aminoethyl pharmacophore group on the potency of rimantadine against influenza virus A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 692-696.	1.0	36
514	Antiviral 2,5-disubstituted imidazo[4,5- <i>c</i>]pyridines: Further optimization of anti-hepatitis C virus activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5111-5114.	1.0	23
515	Synthesis and antiviral activities of new acyclic and double-headed nucleoside analogues. <i>Bioorganic Chemistry</i> , 2007, 35, 221-232.	2.0	9
516	Improved crystallization of the coxsackievirus B3 RNA-dependent RNA polymerase. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2007, 63, 495-498.	0.7	8
517	2'-C-Methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. <i>Antiviral Research</i> , 2007, 73, 161-168.	1.9	52
518	Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. <i>Antiviral Research</i> , 2007, 73, 192-196.	1.9	18
519	Cidofovir is effective against caprine herpesvirus 1 infection in goats. <i>Antiviral Research</i> , 2007, 74, 138-141.	1.9	15
520	In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. <i>Veterinary Microbiology</i> , 2007, 122, 43-51.	0.8	66
521	239 EMBRYOTOXICITY ASSAY FOR ANTIVIRAL COMPOUND BPIP (5-[(4-BROMOPHENYL)METHYL]-2-PHENYL-5H-IMIDAZO[4,5- <i>c</i>]PYRIDINE) IN BOVINE IN VITRO-PRODUCED EMBRYOS. <i>Reproduction, Fertility and Development</i> , 2007, 19, 235.	0.1	1
522	Potent inhibition of genital herpesvirus infection in goats by cidofovir. <i>Antiviral Therapy</i> , 2007, 12, 977-9.	0.6	2

#	ARTICLE	IF	CITATIONS
523	Potent Inhibition of Genital Herpesvirus Infection in Goats by Cidofovir. <i>Antiviral Therapy</i> , 2007, 12, 977-980.	0.6	10
524	Synthesis and Anti-BVDV Activity of Acridones As New Potential Antiviral Agents ¹ . <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2621-2627.	2.9	71
525	Synthesis, in Vitro Antiviral Evaluation, and Stability Studies of Novel $\hat{\pm}$ -Borano-Nucleotide Analogues of 9-[2-(Phosphonomethoxy)ethyl]adenine and (R)-9-[2-(Phosphonomethoxy)propyl]adenine. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7799-7806.	2.9	49
526	Synthesis of 6-Arylthio Analogs of 2 $\hat{\epsilon}$,3 $\hat{\epsilon}$ -Dideoxy-3 $\hat{\epsilon}$ -Fluoroguanosine and Their Effect against Hepatitis B Virus Replication. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2006, 25, 655-665.	0.4	4
527	Synthesis and Antiviral Evaluation of Cyclic and Acyclic 2-Methyl-3-hydroxy-4-pyridinone Nucleoside Derivatives. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 43-50.	2.9	21
528	Viral load quantitation of SARS-coronavirus RNA using a one-step real-time RT-PCR. <i>International Journal of Infectious Diseases</i> , 2006, 10, 32-37.	1.5	24
529	Clinical effect of cidofovir and a diet supplemented with <i>Spirulina platensis</i> in white spot syndrome virus (WSSV) infected specific pathogen-free <i>Litopenaeus vannamei</i> juveniles. <i>Aquaculture</i> , 2006, 255, 600-605.	1.7	29
530	Hemin potentiates the anti-hepatitis C virus activity of the antimalarial drug artemisinin. <i>Biochemical and Biophysical Research Communications</i> , 2006, 348, 139-144.	1.0	64
531	Synthesis and primary antiviral activity evaluation of 3-hydrazono-5-nitro-2-indolinone derivatives. <i>Arkivoc</i> , 2006, 2006, 109-118.	0.3	21
532	Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. <i>Nature</i> , 2006, 439, 745-748.	13.7	180
533	Substituted 5-benzyl-2-phenyl-5H-imidazo[4,5-c]pyridines: A new class of pestivirus inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5345-5349.	1.0	28
534	Synthesis, conformational characteristics and anti-influenza virus A activity of some 2-adamantylsubstituted azacycles. <i>Bioorganic Chemistry</i> , 2006, 34, 248-273.	2.0	23
535	Heterocyclic rimantadine analogues with antiviral activity. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3341-3348.	1.4	109
536	Synthesis of 5-aryltriazole ribonucleosides via Suzuki coupling and promoted by microwave irradiation. <i>Tetrahedron Letters</i> , 2006, 47, 6727-6731.	0.7	29
537	A Novel, Highly Selective Inhibitor of Pestivirus Replication That Targets the Viral RNA-Dependent RNA Polymerase. <i>Journal of Virology</i> , 2006, 80, 149-160.	1.5	78
538	Hepatitis B virus replication causes oxidative stress in HepAD38 liver cells. <i>Molecular and Cellular Biochemistry</i> , 2006, 290, 79-85.	1.4	51
539	Introduction to the Special Issue dedicated to Prof. Erik De Clercq for reaching the Professor Emeritus status at the Katholieke Universiteit Leuven. <i>Antiviral Research</i> , 2006, 71, 75-76.	1.9	1
540	Selective inhibitors of hepatitis C virus replication. <i>Antiviral Research</i> , 2006, 71, 363-371.	1.9	50

#	ARTICLE	IF	CITATIONS
541	The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. <i>Hepatology</i> , 2006, 43, 761-770.	3.6	272
542	Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2-â€²-C-Methylcytidine, the Active Component of Valopicitabine. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3444-3446.	1.4	56
543	Poly(I)-Poly(C 12 U) but Not Ribavirin Prevents Death in a Hamster Model of Nipah Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1768-1772.	1.4	107
544	The Anti-Yellow Fever Virus Activity of Ribavirin Is Independent of Error-Prone Replication. <i>Molecular Pharmacology</i> , 2006, 69, 1461-1467.	1.0	80
545	Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis. <i>Circulation</i> , 2006, 114, 565-573.	1.6	100
546	Preliminary report of anti-hepatitis C virus activity of chloroquine and hydroxychloroquine in huh-5-2 cell line. <i>Indian Journal of Pharmaceutical Sciences</i> , 2006, 68, 538.	1.0	4
547	An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge. <i>Journal of Virology</i> , 2005, 79, 13139-13149.	1.5	372
548	The Predominant Mechanism by Which Ribavirin Exerts Its Antiviral Activity In Vitro against Flaviviruses and Paramyxoviruses Is Mediated by Inhibition of IMP Dehydrogenase. <i>Journal of Virology</i> , 2005, 79, 1943-1947.	1.5	254
549	ANTIVIRAL POTENTIAL OF A NEW GENERATION OF ACYCLIC NUCLEOSIDE PHOSPHONATES, THE 6-[2-(PHOSPHONOMETHOXY)ALKOXY]-2,4-DIAMINOPYRIMIDINES. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2005, 24, 331-341.	0.4	66
550	Growth kinetics of SARS-coronavirus in Vero E6 cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 329, 1147-1151.	1.0	32
551	Novel Acyclic Nucleoside Phosphonate Analogues with Potent Anti-Hepatitis B Virus Activities. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1177-1180.	1.4	48
552	Synthesis and Antiviral Evaluation of Cis-Substituted Cyclohexenyl and Cyclohexanyl Nucleosides. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 450-456.	2.9	33
553	Exchanging the Yellow Fever Virus Envelope Proteins with Modoc Virus prM and E Proteins Results in a Chimeric Virus That Is Neuroinvasive in SCID Mice. <i>Journal of Virology</i> , 2004, 78, 7418-7426.	1.5	25
554	Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2267-2273.	1.4	64
555	The Interferon Inducer Ampligen [Poly(I)-Poly(C 12 U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 267-274.	1.4	55
556	Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. <i>Antiviral Research</i> , 2004, 62, 121-123.	1.9	41
557	In vivo monitoring of acute flavivirus (Modoc) encephalitis with regional and whole-brain quantitative diffusion magnetic resonance imaging. <i>Journal of NeuroVirology</i> , 2004, 10, 255-259.	1.0	2
558	Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. <i>Reviews in Medical Virology</i> , 2004, 14, 289-300.	3.9	74

#	ARTICLE	IF	CITATIONS
559	Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5-nitrobenzotrile. <i>Journal of Medical Virology</i> , 2004, 72, 263-267.	2.5	18
560	In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 264-268.	1.0	530
561	Rodent models for the study of therapy against flavivirus infections. <i>Antiviral Research</i> , 2004, 63, 67-77.	1.9	20
562	Impact of Direct Virus-Induced Neuronal Dysfunction and Immunological Damage on the Progression of Flavivirus (Modoc) Encephalitis in a Murine Model. <i>Journal of NeuroVirology</i> , 2003, 9, 69-78.	1.0	16
563	Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. <i>BMC Microbiology</i> , 2003, 3, 25.	1.3	27
564	A rapid and convenient variant of fusion-PCR to construct chimeric flaviviruses. <i>Journal of Virological Methods</i> , 2003, 108, 67-74.	1.0	15
565	Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. <i>Antiviral Research</i> , 2003, 57, 25-33.	1.9	56
566	The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (<i>Musa spp.</i>). <i>Antiviral Research</i> , 2003, 59, 121-126.	1.9	25
567	Spiro[pyrrolidine-2,2- ϵ -adamantanes]: Synthesis, Antiinfluenza Virus Activity and Conformational Properties.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
568	Synthesis and antiviral evaluation of 3-hydroxy-2-methylpyridin-4-one dideoxynucleoside derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 4371-4374.	1.0	10
569	Heterocyclic rimantadine analogues with antiviral activity. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 5485-5492.	1.4	50
570	Spiro[pyrrolidine-2,2- ϵ -adamantanes]: synthesis, anti-influenza virus activity and conformational properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1699-1703.	1.0	129
571	Selective inhibition of hepatitis B virus replication by RNA interference. <i>Biochemical and Biophysical Research Communications</i> , 2003, 309, 482-484.	1.0	80
572	Prospects for Antiviral Therapy. <i>Advances in Virus Research</i> , 2003, 61, 511-553.	0.9	16
573	Synthesis and Antiviral Evaluation of Ribavirin Congeners Containing a Hexitol Moiety. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2003, 22, 849-851.	0.4	2
574	Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 777-782.	1.4	55
575	Are the 2-Isomers of the Drug Rimantadine Active Anti-Influenza a Agents?. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 153-164.	0.3	40
576	Ribavirin Derivatives with a Hexitol Moiety: Synthesis and Antiviral Evaluation. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 23-30.	0.3	3

#	ARTICLE	IF	CITATIONS
577	Non-Nucleoside Inhibitors of HCMV Replication. , 2003, 24, 171-181.		0
578	Acute Encephalitis, a Poliomyelitis-like Syndrome and Neurological Sequelae in a Hamster Model for Flavivirus Infections. Brain Pathology, 2003, 13, 279-290.	2.1	24
579	Selective Inhibitors of Hepatitis B Virus Replication. Anti-Infective Agents in Medicinal Chemistry, 2003, 2, 227-240.	0.9	10
580	Effect of 5-Iodo-2-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice. Antimicrobial Agents and Chemotherapy, 2002, 46, 2842-2847.	1.4	45
581	Sulphated and Sulphonated Polymers Inhibit the Initial Interaction of Hepatitis B Virus with Hepatocytes. Antiviral Chemistry and Chemotherapy, 2002, 13, 157-164.	0.3	24
582	Human Herpesvirus 8 Gene Encodes a Functional Thymidylate Synthase. Journal of Virology, 2002, 76, 10530-10532.	1.5	20
583	Genome sequence analysis of Tamana bat virus and its relationship with the genus Flavivirus. Journal of General Virology, 2002, 83, 2443-2454.	1.3	69
584	Gammaherpesviruses encode functional dihydrofolate reductase activity. Biochemical and Biophysical Research Communications, 2002, 297, 756-759.	1.0	2
585	Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo. Antiviral Research, 2002, 55, 179-188.	1.9	6
586	2-chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Research, 2002, 55, 413-424.	1.9	46
587	Complete Genome Sequence, Taxonomic Assignment, and Comparative Analysis of the Untranslated Regions of the Modoc Virus, a Flavivirus with No Known Vector. Virology, 2002, 293, 125-140.	1.1	46
588	Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3' untranslated region of flaviviruses with no known vector. Journal of General Virology, 2002, 83, 1875-1885.	1.3	40
589	Infection of SCID mice with Montana Myotis leukoencephalitis virus as a model for flavivirus encephalitis. Journal of General Virology, 2002, 83, 1887-1896.	1.3	26
590	Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood, 2001, 98, 3554-3561.	0.6	227
591	Novel 3-(2-Adamantyl)pyrrolidines with potent activity against influenza A virus—identification of aminoadamantane derivatives bearing two pharmacophoric amine groups. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2137-2142.	1.0	60
592	Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Reviews in Medical Virology, 2001, 11, 381-395.	3.9	157
593	Potent inhibition of hemangiosarcoma development in mice by cidofovir. International Journal of Cancer, 2001, 92, 161-167.	2.3	27
594	A Novel Model for the Study of the Therapy of Flavivirus Infections Using the Modoc Virus. Virology, 2001, 279, 27-37.	1.1	48

#	ARTICLE	IF	CITATIONS
595	A chemiluminescence detection method of hantaviral antigens in neutralisation assays and inhibitor studies. <i>Journal of Virological Methods</i> , 2001, 96, 17-23.	1.0	53
596	Anti-herpesvirus activity of (1 <i>S</i> ,2 <i>R</i>)-9-[[1 <i>S</i> ,2 <i>S</i> -bis(hydroxymethyl)-cycloprop-1 <i>yl</i>]methyl]guanine (A-5021) in vitro and in vivo. <i>Antiviral Research</i> , 2001, 49, 115-120.	1.9	17
597	The anti-herpesvirus activity of (1 <i>S</i> ,2 <i>R</i>)-9-[[1 <i>S</i> ,2 <i>S</i> -bis(hydroxymethyl)cycloprop-1 <i>yl</i>]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. <i>Antiviral Research</i> , 2001, 49, 121-127.	1.9	12
598	Angiogenesis: regulators and clinical applications. <i>Biochemical Pharmacology</i> , 2001, 61, 253-270.	2.0	643
599	Effect of TNP-470 (AGM-1470) on the Growth of Rat Rhabdomyosarcoma Tumors of Different Sizes. <i>Cancer Investigation</i> , 2001, 19, 35-40.	0.6	11
600	ACYCLIC/CARBOCYCLIC GUANOSINE ANALOGUES AS ANTI-HERPESVIRUS AGENTS. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2001, 20, 271-285.	0.4	60
601	Efficacy of 2-Amino-7-(1,3-Dihydroxy-2-Propoxymethyl)Purine for Treatment of Vaccinia Virus (Orthopoxvirus) Infections in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 84-87.	1.4	50
602	<i>In vitro</i> Activity of Polyhydroxycarboxylates against Herpesviruses and Hiv. <i>Antiviral Chemistry and Chemotherapy</i> , 2001, 12, 337-345.	0.3	13
603	Synthesis, Antiretroviral and Antioxidant Evaluation of a Series of New Benzo[b]furan Derivatives. <i>Arzneimittelforschung</i> , 2001, 51, 156-162.	0.5	3
604	Methods in Anti-HCMV Research. , 2000, 33, 129-152.		1
605	Hydrogels containing monocaprin prevent intravaginal and intracutaneous infections with HSV-2 in mice: Impact on the search for vaginal microbicides. , 2000, 61, 107-110.		51
606	Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. <i>Journal of Viral Hepatitis</i> , 2000, 7, 79-83.	1.0	62
607	Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. <i>Journal of Viral Hepatitis</i> , 2000, 7, 161-165.	1.0	125
608	Antiviral activity of ganciclovir elaidic acid ester against herpesviruses. <i>Antiviral Research</i> , 2000, 45, 157-167.	1.9	15
609	Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. <i>Antiviral Research</i> , 2000, 48, 117-124.	1.9	36
610	Perspectives for the Treatment of Infections with <i>Flaviviridae</i> . <i>Clinical Microbiology Reviews</i> , 2000, 13, 67-82.	5.7	130
611	Use of Cotton Rats to Evaluate the Efficacy of Antivirals in Treatment of Measles Virus Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1146-1152.	1.4	28
612	Perspectives for the Treatment of Infections with <i>Flaviviridae</i> . <i>Clinical Microbiology Reviews</i> , 2000, 13, 67-82.	5.7	134

#	ARTICLE	IF	CITATIONS
613	Hydroxyurea Potentiates the Antitherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2885-2892.	1.4	11
614	Budding Yeast as a Screening Tool for Discovery of Nucleoside Analogs for Use in HSV-1 TK Suicide-Gene Therapy. <i>BioTechniques</i> , 1999, 27, 772-777.	0.8	3
615	Modulation of Fibroblast Growth Factor-2 Receptor Binding, Signaling, and Mitogenic Activity by Heparin-Mimicking Polysulfonated Compounds. <i>Molecular Pharmacology</i> , 1999, 56, 204-213.	1.0	95
616	Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. <i>Journal of Viral Hepatitis</i> , 1999, 6, 229-236.	1.0	70
617	Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation. <i>Journal of Virological Methods</i> , 1999, 81, 155-158.	1.0	10
618	Synthesis and Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclobutane Ring. <i>Archiv Der Pharmazie</i> , 1999, 332, 348-352.	2.1	12
619	Antitumor Potential of Acyclic Nucleoside Phosphonates. <i>Nucleosides & Nucleotides</i> , 1999, 18, 759-771.	0.5	41
620	THE IMMUNOSUPPRESSIVE AGENT MYCOPHENOLATE MOFETIL MARKEDLY POTENTIATES THE ACTIVITY OF LOBUCAVIR [1R(1??,2??,3??)]-9-[2,3-BIS(HYDROXYMETHYL)-CYCLOBUTYL]GUANINE AGAINST DIFFERENT HERPES VIRUSES1. <i>Transplantation</i> , 1999, 67, 760-764.	0.5	19
621	A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. <i>Cancer Research</i> , 1999, 59, 2376-83.	0.4	33
622	Infections with flaviviridae. <i>Verhandelingen - Koninklijke Academie Voor Geneeskunde Van België</i> , 1999, 61, 661-97; discussion 697-9.	0.2	7
623	Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. <i>Gene Therapy</i> , 1998, 5, 419-426.	2.3	23
624	Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. <i>Antiviral Research</i> , 1998, 40, 53-56.	1.9	42
625	7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase. <i>FEBS Letters</i> , 1998, 438, 91-95.	1.3	66
626	Inhibitory effect of 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) on hepatitis B virus replication in vitro. <i>Journal of Hepatology</i> , 1998, 28, 101.	1.8	0
627	The influences of immunosuppressive agents on HBV replication in vitro. <i>Journal of Hepatology</i> , 1998, 28, 102.	1.8	0
628	Differential anti-hepatitis B virus activity in vitro of three potent of inosine monophosphate dehydrogenase inhibitors: mycophenolic acid (MPA), 5-ethynyl-1-β-d-ribofuranosyl-midazole-4-carboxamide (EICAR) and ribavirin. <i>Journal of Hepatology</i> , 1998, 28, 103.	1.8	0
629	Polyanion Inhibitors of HIV and Other Viruses. 7. Polyanionic Compounds and Polyzwitterionic Compounds Derived from Cyclodextrins as Inhibitors of HIV Transmission. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4927-4932.	2.9	48
630	Inhibitory Effects of Novel Nucleoside and Nucleotide Analogues on Epstein-Barr Virus Replication. <i>Antiviral Chemistry and Chemotherapy</i> , 1998, 9, 275-282.	0.3	46

#	ARTICLE	IF	CITATIONS
631	Broad-Spectrum Antiviral Activity and Mechanism of Antiviral Action of the Fluoroquinolone Derivative K-12. <i>Antiviral Chemistry and Chemotherapy</i> , 1998, 9, 403-411.	0.3	49
632	Synthesis, Antiviral and Cytostatic Activities of Carbocyclic Nucleosides Incorporating a Modified Cyclopentane Ring. Part 2: Adenosine and Uridine Analogues. <i>Nucleosides & Nucleotides</i> , 1998, 17, 1255-1266.	0.5	11
633	The Novel Immunosuppressive Agent Mycophenolate Mofetil Markedly Potentiates the Antiherpesvirus Activities of Acyclovir, Ganciclovir, and Penciclovir In Vitro and In Vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 216-222.	1.4	136
634	Intracellular Metabolism of the N7-Substituted Acyclic Nucleoside Analog 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purine, a Potent Inhibitor of Herpesvirus Replication. <i>Molecular Pharmacology</i> , 1998, 53, 157-165.	1.0	34
635	In Vitro and In Vivo Inhibition of Murine Gamma Herpesvirus 68 Replication by Selected Antiviral Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 170-172.	1.4	49
636	The Antiherpesvirus Activity of H2G [(R)-9-[4-Hydroxy-2-(Hydroxymethyl)Butyl]Guanine] Is Markedly Enhanced by the Novel Immunosuppressive Agent Mycophenolate Mofetil. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 3285-3289.	1.4	31
637	The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. <i>Cancer Research</i> , 1998, 58, 384-8.	0.4	42
638	Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir. <i>Cancer Research</i> , 1998, 58, 2562-7.	0.4	22
639	HPMPC (cidofovir), PMEA (adefovir) and Related Acyclic Nucleoside Phosphonate Analogues: A Review of their Pharmacology and Clinical Potential in the Treatment of Viral Infections. <i>Antiviral Chemistry and Chemotherapy</i> , 1997, 8, 1-23.	0.3	214
640	Nucleosides and Nucleotides. Part 154. New Neplanocin Analogues. VIII. Synthesis and Biological Activity of 6'-C-Ethyl, -Ethenyl, and -Ethylnyl Derivatives of Neplanocin A.. <i>Chemical and Pharmaceutical Bulletin</i> , 1997, 45, 1163-1168.	0.6	12
641	Antiviral drug susceptibility of human herpesvirus 8. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2754-2756.	1.4	161
642	Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. <i>Antiviral Research</i> , 1997, 36, 35-42.	1.9	51
643	Mycophenolate Mofetil markedly enhances the antiviral activity of acyclovir, ganciclovir and penciclovir against herpes simplex virus (wild type and TK ⁻ strains) and human cytomegalovirus. <i>Antiviral Research</i> , 1997, 34, A47.	1.9	0
644	Synthesis and antiviral evaluation of benzyl-substituted thiopurine and tiazofurin derivatives. <i>Antiviral Research</i> , 1997, 34, A55.	1.9	0
645	Antiviral activity of a novel compound P-4018 against different strains of herpes simplex virus in vitro and in vivo. <i>Antiviral Research</i> , 1997, 34, A76.	1.9	0
646	Differential antiviral activity of several IMP dehydrogenase inhibitors. <i>Antiviral Research</i> , 1997, 34, A87.	1.9	1
647	The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis. <i>Oncology Research</i> , 1997, 9, 173-81.	0.6	31
648	Polyanion Inhibitors of Human Immunodeficiency Virus and Other Viruses. Part 2. Polymerized Anionic Surfactants Derived from Amino Acids and Dipeptides. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1626-1634.	2.9	20

#	ARTICLE	IF	CITATIONS
649	Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2. Journal of Medicinal Chemistry, 1996, 39, 3307-3318.	2.9	144
650	Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Research, 1996, 30, 125-132.	1.9	106
651	Mechanism of the Antiviral Activity of New Aurintricarboxylic Acid Analogues. Antiviral Chemistry and Chemotherapy, 1996, 7, 142-152.	0.3	14
652	Effect of Polyanionic Compounds on Intracutaneous and Intravaginal Herpesvirus Infection in Mice. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 8??12.	0.3	18
653	Human cytomegalovirus modulates the Ca ²⁺ response to vasopressin and ATP in fibroblast cultures. Cell Calcium, 1995, 18, 111-119.	1.1	8
654	Effect of polyanionic compounds on intracutaneous and intravaginal herpes virus infection in mice: Impact on the search for vaginal microbicides. Antiviral Research, 1995, 26, A333.	1.9	1
655	Human Cytomegalovirus Stimulates Thymidylate Synthase in Human Embryonic Lung Cells: A Possible Target for Anti-HCMV Therapy?. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 1153-1156.	0.4	3
656	In vivo Antiretroviral Efficacy of Oral bis(POM)-PMEA, the bis(Pivaloyloxymethyl)prodrug of 9-(2-Phosphonylmethoxyethyl) adenine (PMEA). Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 767-770.	0.4	19
657	In vivo antiherpesvirus activity of N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine. Antimicrobial Agents and Chemotherapy, 1995, 39, 56-60.	1.4	32
658	Anti-HIV and anti-HCMV Activities of New Aurintricarboxylic Acid Analogues. Antiviral Chemistry and Chemotherapy, 1995, 6, 179-186.	0.3	4
659	Absence of Infectious Retinitis after Injection of Human Cytomegalovirus into Rabbit Eyes. Journal of Infectious Diseases, 1995, 171, 782-787.	1.9	6
660	Differential antiviral activity of derivatized dextrans. Biochemical Pharmacology, 1995, 50, 743-751.	2.0	48
661	Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity. Journal of Acquired Immune Deficiency Syndromes, 1995, 10, 8-12.	0.3	9
662	The N-7-substituted acyclic nucleoside analog 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine is a potent and selective inhibitor of herpesvirus replication. Antimicrobial Agents and Chemotherapy, 1994, 38, 2710-2716.	1.4	46
663	In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrobial Agents and Chemotherapy, 1994, 38, 256-259.	1.4	42
664	Host Defense Mechanisms Against Murine Cytomegalovirus Infection Induced by Poly I:C in Severe Combined Immune Deficient (SCID) Mice. Experimental Biology and Medicine, 1994, 207, 191-196.	1.1	6
665	Antiviral activity of a sulphated polysaccharide from the red seaweed <i>nothogenia fastigiata</i> . Biochemical Pharmacology, 1994, 47, 2187-2192.	2.0	81
666	Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. Biochemical Pharmacology, 1994, 47, 39-41.	2.0	38

#	ARTICLE	IF	CITATIONS
667	Calcineurin as a possible new target for treatment of Parkinson's disease. <i>Medical Hypotheses</i> , 1994, 43, 132-134.	0.8	15
668	New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity. <i>Verhandelingen - Koninklijke Academie Voor Geneeskunde Van België</i> , 1994, 56, 561-92.	0.2	1
669	Efficacy of oral 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) in the treatment of retrovirus and cytomegalovirus infections in mice. <i>Journal of Medical Virology</i> , 1993, 39, 167-172.	2.5	32
670	Protective activity of lipid A analogue GLA-60 against murine cytomegalovirus infection in mice. <i>Journal of Medical Virology</i> , 1993, 40, 222-227.	2.5	4
671	Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. <i>Journal of Medical Virology</i> , 1993, 41, 242-246.	2.5	108
672	Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993, 12, 269-279.	1.3	40
673	Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1993, 12, 437-446.	1.3	19
674	Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication. <i>Antiviral Research</i> , 1993, 21, 197-216.	1.9	41
675	Strategies for the treatment and prevention of cytomegalovirus infections. <i>International Journal of Antimicrobial Agents</i> , 1993, 3, 187-204.	1.1	4
676	<i>In vitro</i> Activity of a Novel Series of Polyoxosilicotungstates against Human Myxo-, Herpes- and Retroviruses. <i>Antiviral Chemistry and Chemotherapy</i> , 1993, 4, 253-262.	0.3	22
677	Protective activity of the lipid A analogue GLA-60 against murine cytomegalovirus infection in immunodeficient mice. <i>Journal of General Virology</i> , 1993, 74, 1399-1403.	1.3	7
678	Poly(Hydroxy)Carboxylates as Selective Inhibitors of Cytomegalovirus and Herpes Simplex Virus Replication. <i>Antiviral Chemistry and Chemotherapy</i> , 1992, 3, 215-222.	0.3	33
679	Therapy for herpesvirus infections. <i>Current Opinion in Infectious Diseases</i> , 1992, 5, 816-826.	1.3	3
680	The mannose-specific plant lectins from <i>Cymbidium</i> hybrid and <i>Epipactis helleborine</i> and the (N-acetylglucosamine)n-specific plant lectin from <i>Urtica dioica</i> are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication in vitro. <i>Antiviral Research</i> , 1992, 18, 191-207.	1.9	230
681	Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. <i>Virology</i> , 1992, 189, 48-58.	1.1	173
682	Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. <i>Journal of Medical Virology</i> , 1992, 37, 67-71.	2.5	62
683	Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. <i>Antiviral Research</i> , 1991, 16, 1-9.	1.9	30
684	Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. <i>Antiviral Research</i> , 1991, 16, 41-52.	1.9	67

#	ARTICLE	IF	CITATIONS
685	Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anticytomegalovirus agents. <i>Journal of Virological Methods</i> , 1991, 35, 27-38.	1.0	22
686	Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 410-416.	1.4	230
687	Inhibitory Effects of Polycations on the Replication of Enveloped Viruses (HIV, HSV, CMV, RSV,) Tj ETQq1 1 0.784314 rgBT /Overlock I 243-248.	0.3	18
688	Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (DHPG). <i>Virology</i> , 1990, 179, 41-50.	1.1	92
689	Sulphated Polymers are Potent and Selective Inhibitors of Various Enveloped Viruses, Including Herpes Simplex Virus, Cytomegalovirus, Vesicular Stomatitis Virus, Respiratory Syncytial Virus, and Toga-, Arena- and Retroviruses. <i>Antiviral Chemistry and Chemotherapy</i> , 1990, 1, 233-240.	0.3	85
690	Detection of substances recognized by antisera directed against vertebrate somatotropin, prolactin and placental lactogen, within the brain of the insect <i>Locusta migratoria</i> : A comparison of immunocytochemical localization patterns. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , 1990, 97, 35-40.	0.7	3
691	Detection of immediate early, early and late antigens of human cytomegalovirus by flow cytometry. <i>Journal of Virological Methods</i> , 1989, 26, 247-254.	1.0	32
692	Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
693	Antiviral Drugs. , 0, , 461-482.		0